[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 497
1. Zervoudis S, Peitsidis P, Iatrakis G, Panourgias E, Koureas A, Navrozoglou I, Dubois JB: Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results. J BUON; 2007 Oct-Dec;12(4):487-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
  • PURPOSE: To analyze, study and interpret the increased levels of tumor markers in breast cancer patients without recurrence or metastasis.
  • Follow-up included frequent serum estimation of CEA, CA 15.3, CA 125, CA 27-29, TPA and TPS tumor markers.
  • RESULTS: Of 358 patients being continuously disease-free, 18 (5%) cases showed false-positive levels of tumor markers, associated with benign conditions and not to cancer recurrence or metastasis.
  • These conditions included ovarian cysts, thyroid disorders, hepatitis, renal stone and sarcoidosis.
  • CONCLUSION: The value of increased tumor markers should be interpreted cautiously because it doesn't always imply disease recurrence.
  • Tumor markers may increase in many benign conditions.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] False Positive Reactions. Female. Follow-Up Studies. Humans. Neoplasm Metastasis. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067207.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Zhang YF, Wang HN, Hong TP: [Ghrelin expression in the tissues of different thyroid diseases]. Beijing Da Xue Xue Bao; 2006 Apr 18;38(2):193-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ghrelin expression in the tissues of different thyroid diseases].
  • OBJECTIVE: To investigate whether ghrelin, a novel endogenous ligand of growth hormone secretagogue receptor (GHS-R), was expressed in the thyroid tissues of different thyroid diseases, and its implication.
  • METHODS: The paraffin-embedded specimens of thyroid tissues from 2000 to 2004 were obtained from 57 patients with different thyroid diseases, including 5 subacute thyroiditis, 8 Hashimoto's thyroiditis, 7 hyperthyroidism (Graves disease), 8 nodular goiter, 5 thyroid adenoma, 3 thyroid lymphoma, 8 papillary carcinoma, 3 follicular carcinoma, 5 medullary carcinoma and 5 undifferentiated carcinoma cases.
  • The specimens of normal peri-adenoma thyroid tissues served as controls.
  • (1) ghrelin expression was undetectable in the thyroid tissues of normal control, subacute thyroiditis, Hashimoto's thyroiditis and Graves disease. (2) ghrelin expression was also undetected in the tissues of nodular goiter, thyroid adenoma and thyroid lymphoma. (3) ghrelin-positive staining was found in the tumor cells of different types of thyroid carcinoma.
  • CONCLUSION: Ghrelin is expressed in malignant epithelial thyroid neoplasms, but not in autoimmune or inflammatory thyroid diseases and benign nodular thyroid diseases.
  • The results indicate that ghrelin expression may play an important role in the occurrence and development of thyroid carcinoma.
  • [MeSH-major] Ghrelin / metabolism. Thyroid Diseases / metabolism. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617365.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ghrelin
  •  go-up   go-down


3. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park DJ, Jang HC, Park SH, Cho BY, Park SY: Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci; 2007 Aug;22(4):621-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
  • The distinction between benign and malignant thyroid tumors is critical for the management of patients with thyroid nodules.
  • We applied immunohistochemical staining for galectin-3, HBME-1, cytokeratin 19 (CK19), high molecular weight cytokeratin (HMWCK), cyclin D1 and p27(kip1) in 295 thyroid lesions to determine their diagnostic accuracy.
  • The expression of all markers was significantly associated with differentiated thyroid carcinoma (DTC).
  • The sensitivity for the diagnosis of DTC was 94.7% with galectin-3, 91.3% with HBME-1, and 90.3% with CK19.
  • Combining these markers, co-expression of galectin-3 and CK19 or galectin-3 and HBME-1 was seen in 93.2% of carcinomas but in none of the benign nodules.
  • These results suggest that 1) galectin-3 is a useful marker in the distinction between benign and malignant thyroid tumors, 2) the combined use of HBME-1 and CK19 can increase the diagnostic accuracy, and 3) the use of CK19 and HMWCK can aid in the differential diagnosis between PC and FC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Thyroid Gland / pathology. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / metabolism. Cyclin D1 / analysis. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Diagnosis, Differential. Galectin 3 / analysis. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Keratin-19 / analysis. Keratins / analysis. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2001;197(4):217-22 [11358005.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):42-8 [10937048.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4806-10 [12364477.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1508-14 [12409728.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Endocr J. 2003 Apr;50(2):173-7 [12803237.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):309-12 [14999471.001]
  • [Cites] Cell Mol Biol Lett. 2004;9(2):305-28 [15213811.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1978 Nov;86A(6):483-6 [716909.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):107-16 [1740296.001]
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Virchows Arch. 1997 Dec;431(6):407-13 [9428928.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):169-74 [9504687.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):806-11 [9626345.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):735-9 [9720501.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):428-33 [10821488.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):1014-9 [11007042.001]
  • (PMID = 17728499.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1B protein, human; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Intracellular Signaling Peptides and Proteins; 0 / Keratin-19; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2693809
  •  go-up   go-down


Advertisement
4. Guimarães GS, Latini FR, Camacho CP, Maciel RM, Dias-Neto E, Cerutti JM: Identification of candidates for tumor-specific alternative splicing in the thyroid. Genes Chromosomes Cancer; 2006 Jun;45(6):540-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidates for tumor-specific alternative splicing in the thyroid.
  • To gain knowledge about whether alternative splicing is linked to thyroid tumorigenesis, we used our prediction database to select targets for analysis.
  • Fifteen putatively new alternative splicing isoforms were selected on the basis of their expression in thyroid libraries and/or their origin in genes previously associated with carcinogenesis.
  • Using a set of 66 normal, benign, and malignant thyroid tissue samples, new splicing events were confirmed by RT-PCR for 13 of 15 genes (a validation rate of 87%).
  • Five genes (PTPN18, ABI3BP, PFDN5, SULF2, and ST5) presented new and/or additional unpredicted isoforms differentially expressed between malignant and benign or normal thyroid tissues, confirmed by sequencing.
  • In addition, real-time PCR analysis revealed that expression of an alternative PFDN5 variant was higher in malignant lesions than in benign lesions or normal tissues.
  • [MeSH-major] Alternative Splicing. Thyroid Gland / metabolism. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16493598.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms
  •  go-up   go-down


5. Zhou C, Wang Y, Aguirre AD, Tsai TH, Cohen DW, Connolly JL, Fujimoto JG: Ex vivo imaging of human thyroid pathology using integrated optical coherence tomography and optical coherence microscopy. J Biomed Opt; 2010 Jan-Feb;15(1):016001
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo imaging of human thyroid pathology using integrated optical coherence tomography and optical coherence microscopy.
  • We evaluate the feasibility of optical coherence tomography (OCT) and optical coherence microscopy (OCM) for imaging of benign and malignant thyroid lesions ex vivo using intrinsic optical contrast.
  • 34 thyroid gland specimens are imaged from 17 patients, covering a spectrum of pathology ranging from normal thyroid to benign disease/neoplasms (multinodular colloid goiter, Hashimoto's thyroiditis, and follicular adenoma) and malignant thyroid tumors (papillary carcinoma and medullary carcinoma).
  • Characteristic features that suggest malignant lesions, such as complex papillary architecture, microfollicules, psammomatous calcifications, or replacement of normal follicular architecture with sheets/nests of tumor cells, can be identified from OCT and OCM images and are clearly differentiable from normal or benign thyroid tissues.
  • With further development of needle-based imaging probes, OCT and OCM could be promising techniques to use for the screening of thyroid nodules and to improve the diagnostic specificity of fine needle aspiration evaluation.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):474-9 [10744825.001]
  • [Cites] Opt Express. 2009 Jan 19;17(2):784-96 [19158891.001]
  • [Cites] Endoscopy. 2000 Dec;32(12):921-30 [11147939.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):687-91 [11856699.001]
  • [Cites] J Endocrinol Invest. 2002 Jan;25(1):39-43 [11885575.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] Head Neck. 2002 Jul;24(7):651-5 [12112538.001]
  • [Cites] J Ultrasound Med. 2003 Feb;22(2):127-31; quiz 132-4 [12562117.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Opt Lett. 2003 Nov 1;28(21):2064-6 [14587816.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1027-31 [14606557.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(2):85-97 [14999139.001]
  • [Cites] Head Neck. 2004 May;26(5):425-34 [15122659.001]
  • [Cites] J Ultrasound Med. 2004 Nov;23(11):1455-64 [15498910.001]
  • [Cites] AJR Am J Roentgenol. 1982 Mar;138(3):499-501 [6978000.001]
  • [Cites] Radiology. 1991 Dec;181(3):683-7 [1947082.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1178-81 [1957169.001]
  • [Cites] J Ultrasound Med. 1994 Feb;13(2):87-90 [7932966.001]
  • [Cites] Ir J Med Sci. 1994 Oct;163(10):451-4 [7814246.001]
  • [Cites] J Urol. 1997 May;157(5):1915-9 [9112562.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2037-9 [9197265.001]
  • [Cites] Am J Gastroenterol. 1997 Oct;92(10):1800-4 [9382040.001]
  • [Cites] Dig Dis Sci. 1998 Jun;43(6):1193-9 [9635607.001]
  • [Cites] J Ultrasound Med. 1998 Aug;17(8):487-96 [9697951.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):561-74 [16185971.001]
  • [Cites] Ultrasound Med Biol. 2005 Oct;31(10):1343-9 [16223637.001]
  • [Cites] Nat Methods. 2005 Dec;2(12):941-50 [16299479.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Diagn Cytopathol. 2006 Jan;34(1):67-76 [16355378.001]
  • [Cites] Opt Lett. 2006 Apr 15;31(8):1076-8 [16625908.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] JAMA. 2006 May 10;295(18):2164-7 [16684987.001]
  • [Cites] Opt Lett. 2006 Oct 15;31(20):2975-7 [17001371.001]
  • [Cites] J Biomed Opt. 2006 Sep-Oct;11(5):054015 [17092164.001]
  • [Cites] Endoscopy. 2007 Jul;39(7):599-605 [17611914.001]
  • [Cites] Opt Lett. 2007 Jul 15;32(14):1971-3 [17632613.001]
  • [Cites] Radiology. 2007 Sep;244(3):865-74 [17630358.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):1001-7 [17767932.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jan;6(1):95-101 [18065276.001]
  • [Cites] Radiology. 2008 Jun;247(3):762-70 [18403624.001]
  • [Cites] Urology. 2000 May;55(5):783-7 [10792101.001]
  • (PMID = 20210448.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075289-14; United States / NCI NIH HHS / CA / R01 CA075289; United States / NCI NIH HHS / CA / R01 CA075289-14; United States / NCI NIH HHS / CA / R01-CA75289-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2844129
  •  go-up   go-down


6. Hommell-Fontaine J, Borda A, Ragage F, Berger N, Decaussin-Petrucci M: Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma. Virchows Arch; 2010 Jun;456(6):661-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma.
  • The presence of pleomorphic tumor giant cells in thyroid carcinomas of follicular cell origin is always worrisome for the pathologist as they first of all refer to anaplastic carcinoma, one of the most aggressive human malignancies.
  • However, non-anaplastic pleomorphic giant cells are well described in other thyroid diseases, most often benign.
  • In this paper, we describe four cases of papillary thyroid carcinoma displaying pleomorphic tumor giant cells with features that differ from those of anaplastic carcinoma.
  • Pleomorphic giant cells were admixed with the underlying thyroid carcinoma and constituted from 5% to 25% of the tumor.
  • Compared to pleomorphic giant cells of anaplastic carcinoma, they reproduced the growth pattern of the underlying carcinoma, had a low mitotic index without necrosis or inflammation, and were reactive with thyroglobulin and thyroid-specific transcription factor-1 and strongly and diffusely positive for cytokeratin AE1/AE3.
  • These cases show that pleomorphic tumor giant cells arising in papillary thyroid carcinomas do not always represent dedifferentiation and progression to anaplastic carcinoma.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Papillary / pathology. Giant Cells / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2009 Jun;37(6):455-65 [19306421.001]
  • [Cites] Endocr J. 2003 Apr;50(2):173-7 [12803237.001]
  • [Cites] Am J Surg Pathol. 1997 Nov;21(11):1261-70 [9351564.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):321-30 [1695118.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):20-5 [8980362.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):319-27 [15681856.001]
  • [Cites] Surgery. 1991 Dec;110(6):956-61; discussion 961-3 [1745983.001]
  • [Cites] Histopathology. 1994 Mar;24(3):205-10 [8200621.001]
  • [Cites] Arch Pathol Lab Med. 1978 Sep;102(9):445-7 [210736.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Acta Cytol. 2002 Sep-Oct;46(5):823-7 [12365214.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):1-18 [16760576.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] World J Surg. 1999 Sep;23(9):975-8; discussion 978-9 [10449831.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1139-45 [11014583.001]
  • [Cites] Am J Surg Pathol. 1980 Aug;4(4):333-41 [6999920.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1184-8 [8960026.001]
  • [Cites] Histopathology. 2002 Sep;41(3):236-43 [12207785.001]
  • [Cites] Pathol Res Pract. 2008;204(3):191-5 [18037575.001]
  • [Cites] Hum Pathol. 2008 Jul;39(7):1080-7 [18495207.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):283-292 [12114789.001]
  • [Cites] World J Surg. 2001 May;25(5):617-22 [11369989.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1256-64 [17667551.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Am J Clin Pathol. 2006 Mar;125(3):399-406 [16613343.001]
  • [Cites] Surgery. 2002 Mar;131(3):245-8 [11894027.001]
  • [Cites] Hum Pathol. 2003 Jul;34(7):666-9 [12874762.001]
  • [Cites] Histopathology. 2007 Jan;50(2):225-31 [17222251.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1054-64 [7522412.001]
  • [Cites] Diagn Cytopathol. 1999 Nov;21(5):307-12 [10527475.001]
  • [Cites] Ann Endocrinol (Paris). 2008 Jun;69(3):174-80 [18423422.001]
  • [Cites] Am J Clin Pathol. 1996 Dec;106(6):765-8 [8980352.001]
  • [Cites] Am J Clin Pathol. 1985 Feb;83(2):135-58 [2578727.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):57-64 [11833496.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):15-24 [1712540.001]
  • [Cites] Int Surg. 2001 Apr-Jun;86(2):117-21 [11918236.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17 ):4744-9 [8062273.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • [Cites] Cancer. 1978 Jun;41(6):2267-75 [657091.001]
  • (PMID = 20414675.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TTF1 protein, human; 68238-35-7 / Keratins
  •  go-up   go-down


7. Abbasova SG, Vysotskii MM, Ovchinnikova LK, Obusheva MN, Digaeva MA, Britvin TA, Bahoeva KA, Karabekova ZK, Kazantzeva IA, Mamedov UR, Manuchin IB, Davidov MI: Cancer and soluble FAS. Bull Exp Biol Med; 2009 Oct;148(4):638-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A test system developed by the authors was used to measure serum concentrations of soluble Fas in patients with malignant and benign tumors of different location and morphology.
  • No appreciable differences in the concentrations of soluble Fas were detected in malignant and benign tumors of the mammary gland, bones, ovaries, and adrenals.
  • In thyroid cancer, soluble Fas levels were higher than in benign and hyperplastic processes in this organ.
  • High level of soluble Fas is associated with late stages of the disease (ovarian cancer, cancer of the corpus uteri, adrenocortical and colorectal cancer) and with poor differentiation of the tumor (ovarian cancer and cancer of the corpus uteri), with local metastases (colorectal and adrenocortical cancer), and with tumor invasion into the myometrial tissue, intestinal wall, and adjacent tissues (cancer of the corpus uteri and colorectal cancer).
  • Soluble Fas levels depended on tumor histogenesis in malignant and benign ovarian tumors.
  • High concentration of soluble Fas was detected in large tumors in patients with ovarian cancer, cancer of the corpus uteri, colorectal cancer, thyroid cancer and adenoma, and in adrenocortical cancer.
  • [MeSH-major] Antigens, CD95 / blood. Neoplasms / blood

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396760.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


8. Shams TM, Samaka RM, Shams ME: Maspin protein expression: a special feature of papillary thyroid carcinoma. J Egypt Natl Canc Inst; 2006 Sep;18(3):274-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin protein expression: a special feature of papillary thyroid carcinoma.
  • BACKGROUND AND AIM: Mammary serine protease inhibitor (Maspin) is down regulated in breast and prostate cancers and is considered as a tumor suppressor gene.
  • On the contrary, it is over expressed in pancreatic and ovarian carcinomas and is reported to be an oncogene rather than a tumor suppressor gene.
  • The studies of maspin expression in thyroid neoplasia, the focus of this study, are limited.
  • We, therefore, carried out this work in order to detect the frequency and pattern of maspin expression in thyroid neoplasia.
  • MATERIAL & METHODS: An immunohistochemical approach was performed on 63 thyroid specimens showing different benign and malignant thyroid lesions.
  • Also, five specimens of the surrounding normal thyroid tissue were included as control.
  • RESULTS: Maspin was only detected in papillary thyroid carcinoma (PTC) and it was negative in all other studied thyroid tissues.
  • There was no statistically significant relation between maspin positive cases and the studied clinicopathological parameters including patient's age, sex and tumor stage.
  • On the other hand, it was statistically significant as regards tumor multicentricity, vascular and lymphatic invasion, as well as lymph node metastasis.
  • CONCLUSIONS: Maspin expression is a special feature of papillary thyroid carcinoma (PTC) which can be used as a therapeutic target.
  • It may be suggested that the genesis of PTC may be different from other types of thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Serpins / analysis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Thyroid Gland / chemistry

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671538.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


9. Park M, Shin JH, Han BK, Ko EY, Hwang HS, Kang SS, Kim JH, Oh YL: Sonography of thyroid nodules with peripheral calcifications. J Clin Ultrasound; 2009 Jul-Aug;37(6):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonography of thyroid nodules with peripheral calcifications.
  • PURPOSE: This study was designed to assess the role of sonography (US) in the differentiation of benign from malignant thyroid nodules with peripheral calcifications.
  • METHODS: Sixty-four thyroid nodules with peripheral calcifications that were detected on US were included in the study.
  • Nineteen nodules (30%) were benign, and 45 nodules (70%) were malignant.
  • We retrospectively compared the US findings of the benign and malignant nodules, including interruption, thickening (>or=0.5 mm and over more than 50% of the circumference) of calcifications, internal echogenicity, margin, and presence of cystic change, size, and shape.
  • RESULTS: Interruption of peripheral calcifications was more common in malignant nodules (84%) than in benign nodules (53%) (OR, 7.9; 95% CI, 1.3-48.4; p < 0.05).
  • Thickening of the peripheral calcification was seen more frequently in malignant nodules (64%) than in benign nodules (11%) (OR, 14.7; 95% CI, 1.8-117.5; p < 0.05).
  • For internal echogenicity, malignant nodules (58%) were more often hypoechoic than benign nodules (OR, 23.6; 95% CI, 2.2-256.3; p < 0.01).
  • The mean tumor size was 1.1 cm for malignant nodules and 1.2 cm for benign nodules (p > 0.05).
  • There were no significant differences for the presence or absence of cystic change, size, shape, and margin between malignant and benign nodules.
  • CONCLUSION: Interruption and thickening of peripheral calcifications and decreased internal echogenicity of a thyroid nodule with peripheral calcifications are in favor of malignancy.
  • [MeSH-major] Calcinosis / ultrasonography. Thyroid Nodule / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Logistic Models. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Thyroid Gland / ultrasonography. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19441092.001).
  • [ISSN] 1097-0096
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Riesco-Eizaguirre G, Santisteban P: A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol; 2006 Oct;155(4):495-512
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates active iodide transport into the thyroid gland and into several extrathyroidal tissues, in particular the lactating mammary gland.
  • Cloning and molecular characterization of the NIS have allowed the investigation of its key role in thyroid physiology as well as its potential pathophysiological and therapeutic implications in benign and malignant thyroid diseases.
  • Similarly, elucidating the mechanisms underlying the regulation of NIS in lactating mammary gland and breast cancer, in which more than 80% of cases express endogenous NIS, may lead to findings that have novel implications for pathophysiology and therapy.
  • One is based on the reinduction of endogenous NIS expression in thyroid and breast cancer by targeting the main mechanisms involving tumoral transformation and dedifferentiation.
  • NIS offers the unique advantage that it can be used both as a reporter and as a therapeutic gene, so that it is possible to image, monitor, and treat the tumor with radioiodide, just as in differentiated thyroid cancer.
  • This review summarizes the main recent findings in NIS research that have a direct impact on diagnosis and therapeutic management.

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990649.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Symporters; 0 / sodium-iodide symporter
  • [Number-of-references] 135
  •  go-up   go-down


11. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC: Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol; 2005 Oct 1;23(28):6846-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A diagnosis was obtained in 69 of these patients, including 37 (54%) with solitary metastases and 32 (46%) with lesions unrelated to the lung primary.
  • Histopathologic examinations of these 32 lesions revealed a second clinically unsuspected malignancy or a recurrence of a previous diagnosed carcinoma in six patients (19%) and a benign tumor or inflammatory lesion in 26 patients (81%).
  • Benign tumors and inflammatory lesions included eight colon adenomas, four Warthin's tumors, one granuloma of the lower jaw, one adenoma of the thyroid gland, one compensatory muscle activity due to vocal chord palsy, two occurrences of arthritis, three occurrences of reflux esophagitis, two occurrences of pancreatitis, two occurrences of diverticulitis, one hemorrhoidal inflammation, and one rib fracture.
  • CONCLUSION: Solitary extrapulmonary FDG accumulations in patients with newly diagnosed lung cancer should be analyzed critically for correct staging and optimal therapy, given that up to half of the lesions may represent unrelated malignancies or benign disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Inflammation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiopharmaceuticals. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192576.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Papacharalampous GX, Korres S, Tzagaroulakis M, Segas I, Ferekidis E: Paraganglioma of the larynx: a case report. Med Sci Monit; 2007 Dec;13(12):CS145-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors are generally considered benign.
  • The tumor was entirely removed along with the left aryepiglottic fold with respect to the surrounding tissues.
  • Histopathological examination showed a benign laryngeal paraganglioma.
  • The differential diagnosis of laryngeal paraganglioma includes typical carcinoid, atypical carcinoid, small-cell neuroendocrine carcinoma, malignant melanoma, and medullary carcinoma of the thyroid gland.
  • Although these tumors are generally considered benign, their surgical removal with respect to the surrounding tissues and maximal possible preservation of laryngeal function is the treatment of choice.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Paraganglioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049441.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


13. Lee SM, Kwak KH: Risk factors and a predictive model for thyroid cancer in Korean women. Cancer Nurs; 2010 Jul-Aug;33(4):310-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors and a predictive model for thyroid cancer in Korean women.
  • BACKGROUND: Thyroid cancer incidence in Korean women has increased radically and is the highest in all cancer types.
  • OBJECTIVE: The aim of the study was to determine the risk factors for thyroid cancer and to develop a predictive model based on these risk factors.
  • To construct a predictive model, the participants selected were 260 female outpatients diagnosed with malignant neoplasm of thyroid gland who had undergone thyroid removal surgery.
  • Nine variables, including occupation, live(d) in coastal region, family history of thyroid cancer, history of benign thyroid tumor, menopause status and weight gain, number of full-term deliveries, abortion, exercise intensity, and stress, remained as statistically significant risk factors in the stepwise regression model.
  • CONCLUSION: The predictive power of the model was relatively good, so it can be used to identify individuals at high risk for thyroid cancer.
  • Thus, it will be possible to detect thyroid cancer in its earliest stage, diminish mortality, and improve quality of life.
  • [MeSH-major] Logistic Models. Risk Assessment / organization & administration. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / etiology. Women's Health

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Women's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495449.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


14. Ersoz S, Sert H, Yandi M, Erem C, Mungan S, Ersoz HO, Cobanoglu U, Hacihasanoglu A: The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. Pathol Oncol Res; 2008 Dec;14(4):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology.
  • The aim of this study is to evaluate the significance of immunohistochemical expression of Galectin-3 in the differential diagnosis of benign and malignant thyroid nodules.
  • We studied the fine needle aspiration specimens of 38 patients who had evaluated for nodular goiter and undergone a thyroid surgery between 2004-2005.
  • None of the cases with a benign thyroid pathology had positive staining for Galectin-3.
  • Galectin-3 immunocytochemical staining, had a sensitivity of 61.5%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 83.3% for thyroid malignancies.
  • For the evaluation of follicular neoplasm, Galectin-3 immunocytochemical staining had a sensitivity of 60%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 50%.
  • Galectin-3 expression in thyrocytes is a strong indicator of a malignant proliferative lesion especially for papillary and to an extent in follicular thyroid neoplasms.
  • Galectin-3 could be used as a supplementary marker for cytological diagnosis.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Papillary / diagnosis. Biomarkers, Tumor / analysis. Galectin 3 / biosynthesis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1993;9(3):345-50 [8519202.001]
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Mayo Clin Proc. 1997 Oct;72(10):913-6 [9379692.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2637-41 [9703921.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3267-71 [7542167.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Pathol Annu. 1989;24 Pt 1:161-98 [2654836.001]
  • [Cites] Acta Cytol. 2006 Jan-Feb;50(1):28-34 [16514837.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2507-11 [1461653.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3494-502 [10550147.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2475-84 [10357421.001]
  • (PMID = 18415710.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


15. Rim SY, Kim SM, Choi HS: Struma ovarii showing clinical characteristics of ovarian malignancy. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare form of ovarian neoplasm, composed entirely or predominantly of thyroid tissue and generally a benign germ cell tumor of the ovary.
  • We experienced a rare case of a postmenopausal woman with benign struma ovarii associated with massive ascites, a complex pelvic mass.
  • No recurrence of the ascites or of the tumor has been observed during the 10-month follow-up.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343201.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


16. Carney JA, Hirokawa M, Lloyd RV, Papotti M, Sebo TJ: Hyalinizing trabecular tumors of the thyroid gland are almost all benign. Am J Surg Pathol; 2008 Dec;32(12):1877-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing trabecular tumors of the thyroid gland are almost all benign.
  • In 1987, Carney et al reported 11 thyroid tumors with the following features: circumscription or encapsulation, trabecular architecture with intratrabecular hyalin and colloid, polygonal and spindle cells, nuclei with frequent grooves and cytoplasmic inclusions, occasional psammoma bodies, and a low mitotic rate.
  • The neoplasms did not recur or metastasize during a follow-up period that averaged 10 years, and they were titled hyalinizing trabecular adenomas.
  • Subsequently, the nuclear features of the neoplasm led to the introduction of 2 modified titles for it, hyalinizing trabecular tumor and hyalinizing trabecular neoplasm.
  • Later, discovery of RET/PTC mutations in the tumor resulted in it being designated as a type of papillary thyroid carcinoma.
  • We studied 119 neoplasms of the type outlined, collected over a 20-year period, for invasion, recurrence and metastasis, and obtained follow-up in 96% of the cases.
  • One tumor showed vascular and capsular invasion, and pulmonary metastasis.
  • We conclude that the overwhelming majority of hyalinizing trabecular tumors of the thyroid behave as benign neoplasms and that, at this time, hyalinizing trabecular adenoma is the most appropriate title for them.
  • [MeSH-major] Adenoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18813121.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Robertson A, Mansberg R, Mansberg V, Van der Wall H, Hooper M: Tumor-induced osteomalacia: a case of diagnostic dilemma. Clin Nucl Med; 2007 Aug;32(8):631-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-induced osteomalacia: a case of diagnostic dilemma.
  • Tumor-induced osteomalacia is typically caused by benign mesenchymal tumors of vascular or skeletal origin.
  • Localization and resection of the FGF-23-secreting tumor offers the best chance of cure.
  • Biochemical investigations showed hypophosphatemia, hyperphosphaturia, and increased alkaline phosphatase, suggesting the presence of an FGF-23-secreting tumor.
  • Thyroid and parathyroid scintigraphy were performed and showed separate areas of focally increased tracer uptake in the neck.
  • The patient underwent octreotide scintigraphy to localize an alternative site of tumor.
  • Histopathology showed a papillary carcinoma of the thyroid, a parathyroid adenoma, and an adrenal adenoma.
  • [MeSH-major] Fractures, Bone / diagnosis. Fractures, Spontaneous / diagnosis. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / diagnosis. Octreotide. Osteomalacia / diagnosis. Osteomalacia / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Radiopharmaceuticals. Whole Body Imaging

  • Genetic Alliance. consumer health - Osteomalacia.
  • MedlinePlus Health Information. consumer health - Fractures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667438.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; RWM8CCW8GP / Octreotide
  •  go-up   go-down


18. Bender O, Karyagar S, Levent Balci F, Yuney E, Kamali S, Ozpacaci T, Mulazimoglu M, Uyanik E, Karyagar SS, Sari YS: Gamma probe (99m)Tc-pertechnetate assisted completion thyroidectomy vs conventional thyroidectomy in differentiated thyroid carcinoma. Hell J Nucl Med; 2009 May-Aug;12(2):138-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma probe (99m)Tc-pertechnetate assisted completion thyroidectomy vs conventional thyroidectomy in differentiated thyroid carcinoma.
  • Patients undergoing partial thyroidectomy for benign diseases may need re-operation if differentiated thyroid carcinoma (DTC) is detected on histopathology.
  • The aim of this study was to determine if using gamma probe during the above surgery in a procedure called: gamma probe completion thyroidectomy (GPCT) could support the diagnosis of DTC tissue and offer an advantage in the surgical treatment of DTC patients.
  • We have studied 100 patients who after bilateral subtotal thyroidectomy for benign disease in several hospitals, were found to have DTC histopathologically and referred to our clinic for subsequent re-operation.
  • We compared retrospectively Group I and Group II in terms of volume of residual thyroid tissue, thyroid stimulating hormone (TSH) values, complication rates and incidence of tumor found in the residual thyroid.
  • Volumes of residual thyroid were also significantly less in Group II (P<0.000).
  • Complications and the incidence of tumor cells found in the residual thyroid tissue between the groups were not statistically different (P>0.05).
  • In conclusion, GPCT in patients with DTC significantly increased the success of this operation in localizing and removing residual thyroid tissue.
  • [MeSH-major] Sodium Pertechnetate Tc 99m. Surgery, Computer-Assisted / methods. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675867.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


19. Rodrigo JP, Rinaldo A, Devaney KO, Shaha AR, Ferlito A: Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma. Head Neck; 2006 Nov;28(11):1032-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma.
  • Thyroid cancers are the most common endocrine malignancies and are being diagnosed with increased frequency in modern clinical practice.
  • Among other diagnostic modalities, fine-needle aspiration (FNA) biopsy of clinically suspicious thyroid nodules is becoming increasingly popular.
  • Preliminary investigations have suggested that molecular diagnostic assays using tumor-specific markers may improve the sensitivity and accuracy of FNA and so may be expected to reduce the frequency of open surgical procedures by identifying those patients with demonstrably benign lesions who do not require definitive surgical excision of their lesions for diagnosis.
  • At the same time, thyroid-specific mRNA assays (especially thyroglobulin mRNA testing) have been used by investigators in the postoperative follow-up of patients with thyroid cancer as a potential means of detecting tumor recurrence in the peripheral blood.
  • Although these studies have not all reported unqualified successes--indeed, some problems based on both technical and biologic limitations have been identified-these assays still hold out the possibility that potentially important new advances in the management of patients with well-differentiated thyroid cancer may be offered by these and other molecular diagnostic methods.
  • [MeSH-major] Biomarkers, Tumor. Molecular Diagnostic Techniques. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16732600.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Fibronectins; 0 / Galectin 3; 0 / Glycoproteins; 0 / HBME-1 antigen; 0 / Membrane Proteins; 0 / oncofetal fibronectin; 124544-67-8 / HMGA1a Protein; 9010-34-8 / Thyroglobulin; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.7.49 / Telomerase
  • [Number-of-references] 80
  •  go-up   go-down


20. Rippe V, Dittberner L, Lorenz VN, Drieschner N, Nimzyk R, Sendt W, Junker K, Belge G, Bullerdiek J: The two stem cell microRNA gene clusters C19MC and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas. PLoS One; 2010;5(3):e9485
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The two stem cell microRNA gene clusters C19MC and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas.
  • Thyroid adenomas are common benign human tumors with a high prevalence of about 5% of the adult population even in iodine sufficient areas.
  • In 4/5 cell lines established from thyroid adenomas with 19q13.4 rearrangements and 5/5 primary adenomas with that type of rearrangement both the C19MC and miR-371-3 cluster were found to be significantly overexpressed compared to controls lacking that particular chromosome abnormality.
  • Of note, the expression of miRNAs miR-520c and miR-373 is known to characterize stem cells and in terms of molecular oncology has been implicated in invasive growth of epithelial cells in vitro and in vivo thus allowing to delineate a distinct molecular subtype of thyroid adenomas.
  • Besides thyroid adenomas rearrangements of 19q13.4 are frequently found in other human neoplasias as well, suggesting that activation of both clusters might be a more general phenomenon in human neoplasias.
  • [MeSH-major] Adenoma / genetics. Chromosomes / ultrastructure. Gene Rearrangement. MicroRNAs / genetics. Multigene Family. Stem Cells / cytology. Thyroid Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. Chromosomes, Human, Pair 19. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence / methods. Molecular Sequence Data. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2009 Jun;37(10):3464-73 [19339516.001]
  • [Cites] J Transl Med. 2009;7:20 [19309508.001]
  • [Cites] Genome Res. 2010 Mar;20(3):311-9 [20032171.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(1-2):48-51 [11474178.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cytogenet Cell Genet. 2001;95(3-4):189-91 [12063398.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Gene. 2002 Oct 16;299(1-2):195-204 [12459267.001]
  • [Cites] Genome Biol. 2004;5(8):R59 [15287981.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 1;40(1):29-32 [2758398.001]
  • [Cites] Cytometry. 1990;11(1):105-9 [2307050.001]
  • [Cites] Cell Biol Int Rep. 1992 Apr;16(4):339-47 [1326410.001]
  • [Cites] Cancer Genet Cytogenet. 1993 May;67(1):1-6 [8504394.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Oct;20(2):201-3 [9331571.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Feb;101(1):42-8 [9460499.001]
  • [Cites] Gene. 1999 Apr 29;231(1-2):77-86 [10231571.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):48-57 [18167339.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Jan 15;180(2):135-9 [18206539.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):202-10 [18193036.001]
  • [Cites] Stem Cells. 2008 Jun;26(6):1506-16 [18403753.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6 [18755890.001]
  • [Cites] J Exp Med. 2008 Oct 27;205(11):2499-506 [18936236.001]
  • [Cites] Childs Nerv Syst. 2009 Jan;25(1):13-20 [18818933.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1221-9 [19141645.001]
  • [Cites] J Cell Biochem. 2009 Apr 15;106(6):1020-30 [19229866.001]
  • [Cites] Cancer Cell. 2009 Dec 8;16(6):533-46 [19962671.001]
  • (PMID = 20209130.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GQ334687/ GQ334688
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN371 microRNA, human; 0 / MicroRNAs; 0 / Oncogene Proteins, Fusion
  • [Other-IDs] NLM/ PMC2831057
  •  go-up   go-down


21. Smith JA, Fan CY, Zou C, Bodenner D, Kokoska MS: Methylation status of genes in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg; 2007 Oct;133(10):1006-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation status of genes in papillary thyroid carcinoma.
  • OBJECTIVES: To determine the methylation status of gene promoter regions using methylation-specific polymerase chain reaction in genes encoding for thyrotropin receptor (TSHR), E-cadherin (ECAD), sodium iodide symporter protein (NIS-L), ataxia telangiectasia mutated (ATM), and death-associated protein kinase (DAPK) proteins and if methylation status correlates with patient variables, tumor factors, or outcome measures among patients with papillary thyroid carcinoma.
  • DESIGN: Database query and retrospective medical chart review for patients with well-differentiated thyroid cancer and nonmalignant thyroid conditions treated at our institutions (1996-2004).
  • Methylation status was then compared with patient variables, tumor factors, and outcome measures for patients with thyroid carcinoma and controls.
  • PATIENTS: The study population comprised 32 patients with papillary thyroid carcinoma and 27 controls.
  • RESULTS: In our patients, all 5 genes were methylated more frequently in papillary thyroid carcinoma than in controls.
  • NIS-L methylation in cancer cells was not associated with methylation in adjacent benign tissue, unlike the other 4 genes.
  • Neither age nor sex affected methylation status, and methylation status did not correlate with extent of the primary tumor or presence of nodal metastasis at diagnosis.
  • CONCLUSIONS: Promoter methylation may be a marker for malignancy in thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / genetics. DNA, Neoplasm / genetics. Receptors, Thyrotropin / metabolism. Symporters / metabolism. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Iodine. Male. Methylation. Middle Aged. Polymerase Chain Reaction. Prognosis. Promoter Regions, Genetic / physiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IODINE, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938324.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Receptors, Thyrotropin; 0 / Symporters; 0 / sodium-iodide symporter; 9679TC07X4 / Iodine
  •  go-up   go-down


22. Zagrodzki P, Nicol F, Arthur JR, Słowiaczek M, Walas S, Mrowiec H, Wietecha-Posłuszny R: Selenoenzymes, laboratory parameters, and trace elements in different types of thyroid tumor. Biol Trace Elem Res; 2010 Apr;134(1):25-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selenoenzymes, laboratory parameters, and trace elements in different types of thyroid tumor.
  • This study was performed to investigate selenoenzyme activities and trace element concentrations in thyroid tissues, with reference to other parameters routinely used to characterize thyroid function.
  • This was to reveal relevant parameters as possible additional markers of tumor grade, clinical course, and prognosis of thyroid disorders.
  • The tissue samples were obtained during surgical treatment (total or near total thyroidectomy) of 122 patients with different types of thyroid tumor.
  • In the majority of cases, thyroid benign or malignant tumors were not accompanied by significant derangement of the gland selenoenzymes and of either intrathyroidal or plasma concentration of selenium.
  • Nevertheless, types I and II iodothyronine deiodinases were the most promising (among selenoenzymes) targets for diagnoses and possibly therapy of thyroid tumors.
  • Higher activities of both enzymes in cases with Graves' disease, as compared with other thyroid lesions, suggest their involvement in the pathogenesis of this condition.
  • Patients with struna nodosa had higher levels of thyroid Zn, Cu, and Pb as compared with papillary carcinoma subjects and also a higher level of Cu than follicular carcinoma cases.
  • The above diagnostics may play a similar role to some of the general thyroid function indices, TSH, anti-TG, anti-TPO, and calcitonin, which can partially distinguish between various thyroid tumors.
  • Multivariate statistical methods should be employed to tackle a broad array of thyroid tumor diagnostic data in a short time.
  • [MeSH-major] Selenium / metabolism. Selenoproteins / metabolism. Thyroid Gland. Thyroid Neoplasms / chemistry. Trace Elements / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Biopsy, Fine-Needle. Female. Humans. Iodide Peroxidase / metabolism. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597722.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Selenoproteins; 0 / Trace Elements; EC 1.11.1.8 / Iodide Peroxidase; H6241UJ22B / Selenium
  •  go-up   go-down


23. Hidalgo AA, Paredes R, Garcia VM, Flynn G, Johnson CS, Trump DL, Onate SA: Altered VDR-mediated transcriptional activity in prostate cancer stroma. J Steroid Biochem Mol Biol; 2007 Mar;103(3-5):731-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stromal cells isolated from benign and malignant associated stroma (BAS and CAS) of a human clinical sample have been determined to contain similar levels of functional 1alpha,25(OH)(2)D(3) receptor (VDR).
  • Chromatin immunoprecipitation (ChIP) assays indicate that in the absence of added ligand VDR interact with the silencing mediator for retinoid and thyroid hormone (SMRT) corepressor in both cell types, with higher recruitment in CAS as compared to BAS cells.
  • [MeSH-major] Prostatic Neoplasms / metabolism. Receptors, Calcitriol / metabolism. Stromal Cells / metabolism. Transcription, Genetic / genetics
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Male. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17368189.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Calcitriol
  •  go-up   go-down


24. Fan SQ, Liang QC, Jiang Y: Thyroid teratoma in an 11-month-old infant. Int J Surg; 2008 Dec;6(6):462-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid teratoma in an 11-month-old infant.
  • We report a case of congenital benign thyroid teratoma in an 11-month-old male infant who was found to have right thyroid gland mass since birth.
  • The tumor was 25 x 20 x 15 mm with whole thin capsule and could be easily dissected from the surrounding normal thyroid tissue at surgery.
  • Histologically, tumor had mature derivatives of the three primordial germ layers with a variety of benign and well-differentiated elements.
  • It was the most conspicuous feature that the tumor was composed mainly of the neurological tissue resembling brain tissue with glial cells and ependymal epithelium components.
  • In summary, benign teratoma of thyroid gland in an 11-month-old infant was morphologically and immunophenotypically identified.
  • [MeSH-major] Teratoma / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19059145.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Ding Z, Ji J, Chen G, Fang H, Yan S, Shen L, Wei J, Yang K, Lu J, Bai Y: Analysis of mitochondrial DNA mutations in D-loop region in thyroid lesions. Biochim Biophys Acta; 2010 Mar;1800(3):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of mitochondrial DNA mutations in D-loop region in thyroid lesions.
  • METHODS: We analyzed the mutations at the mitochondrial DNA (mtDNA) in patients with different thyroid lesions.
  • In particular, in order to investigate if the accumulation of mtDNA mutations play a role in tumor progression, we studied the highly variable main control region of mtDNA, the displacement-loop (D-loop) in patients with non-tumor nodular goiters, with benign thyroid adenomas, and with malignant thyroid carcinomas.
  • Total thyroid tumor or goiter samples were obtained from 101 patients, matched with nearby normal tissue and blood from the same subject.
  • RESULTS: Noticeably, mitochondrial microsatellite instability (mtMSI) was detected in 2 of 19 nodular goiters (10.53%), and 8 of 77 (10.39%) malignant thyroid carcinomas.
  • In addition, 6 patients, including 5 (6.49%) with malignant thyroid carcinomas and 1 (5.26%) with nodular goiter, were found to harbor point mutations.
  • GENERAL SIGNIFICANCE: Our results indicate that mtDNA alterations in the D-loop region could happen before tumorigenesis in thyroid, and they might also accumulate during tumorigenesis.
  • [MeSH-major] DNA, Mitochondrial / genetics. Goiter / genetics. Microsatellite Instability. Mutation. Thyroid Diseases / genetics. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19463899.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Mitochondrial
  •  go-up   go-down


26. Hussein HA, Mebeed AH, Saber TKh, Farhat IG: Hyperparathyroidism with bone tumor-like presentation, approach for diagnosis and surgical intervention. J Egypt Natl Canc Inst; 2009 Mar;21(1):1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperparathyroidism with bone tumor-like presentation, approach for diagnosis and surgical intervention.
  • AIM OF WORK: This work aims to find out a clinical approach for diagnosis of cases with hyperparathyroidism presented with bone tumor like condition as first and main presentation in order to differentiate primary bone tumors or secondary bone metastases from different types of hyperparathyroidism and to clear out the indications and type of surgery in such cases.
  • During this period we followed 45 cases of hyperparathyroidism (HPT) presented with a main complaint of bone tumor-like lesion.
  • RESULTS: Preoperative diagnosis was: 80% cases of primary hyperparathyroidism (pHPT), 15.5% cases of secondary hyperparathyroidism (sHPT), 4.5% tertiary hyperparathyroidism (tHPT), benign adenoma in 73.3%, diffuse hyperplasia in 8.8% and one case of parathyroid carcinoma.
  • Intraoperative ultrasound was useful in detection of 2 additional cases in the thyroid lobe tissue.
  • CONCLUSION: Hyperparathyroidism should be suspected in all cases with bone tumor-like presentation or even in earlier disease complain of bony or muscle aches.
  • Intact P.T.H and calcium (total &ionic), renal functions, 24 hours urine calcium, neck ultrasonography, and Tc 99m pertechnitate/Tc99m sestsmibi subtraction scan can establish the diagnosis.
  • KEY WORDS: Hyperparathyroidism - Bone tumor-like presentation - Diagnosis - Surgical approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601966.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


27. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, Kim J, Kim HS, Byun JS, Lee DH, Thyroid Study Group, Korean Society of Neuro- and Head and Neck Radiology: Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology; 2008 Jun;247(3):762-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study.
  • PURPOSE: To retrospectively evaluate the diagnostic accuracy of ultrasonographic (US) criteria for the depiction of benign and malignant thyroid nodules by using tissue diagnosis as the reference standard.
  • From January 2003 through June 2003, 8024 consecutive patients had undergone thyroid US at nine affiliated hospitals.
  • A total of 831 patients (716 women, 115 men; mean age, 49.5 years +/- 13.8 [standard deviation]) with 849 nodules (360 malignant, 489 benign) that were diagnosed at surgery or biopsy were included in this study.
  • The US findings for benign nodules were isoechogenicity (sensitivity, 56.6%; specificity, 88.1%; P < .001) and a spongiform appearance (sensitivity, 10.4%; specificity, 99.7%; P < .001).
  • For thyroid nodules with a diameter of 1 cm or less, the sensitivity of microcalcifications was lower than that in larger nodules (36.6% vs 51.4%, P < .05).
  • CONCLUSION: Shape, margin, echogenicity, and presence of calcification are helpful criteria for the discrimination of malignant from benign nodules; the diagnostic accuracy of US criteria is dependent on tumor size.
  • [MeSH-major] Thyroid Nodule / ultrasonography
  • [MeSH-minor] Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Regression Analysis. Retrospective Studies. Sensitivity and Specificity

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • [CommentIn] Radiology. 2008 Jun;247(3):602-4 [18487528.001]
  • (PMID = 18403624.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


28. Hedayati M, Kołomecki K, Pasieka Z, Korzeniowska M, Kuzdak K: [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors]. Endokrynol Pol; 2005 May-Jun;56(3):252-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of VEGF and VEGF receptor concentrations in patients with benign and malignant thyroid tumors].
  • Assessment of the tissue expression and measurement of the concentrations of angiogenic and antiangiogenic factors, contributing to this process, in body fluids, can be used not only for an early diagnosis of tumors and their staging but also as an important parameter of treatment efficiency evaluation.
  • The aim of this study is to evaluate the concentrations of crucial angiogenic cytokine VEGF and its soluble receptors in peripheral blood of patients with benign and malignant thyroid tumors.
  • The study comprised 35 patients with thyroid cancer and 10 patients with follicular neoplasm, both diagnosed by means of ultrasound-guided fine-needle aspiration biopsy.
  • Analysing obtained results, we demonstrated high VEGF concentrations and low soluble VEGF receptor concentrations in patients with benign and malignant thyroid tumors.
  • This fact confirms a vital role of VEGF in angiogenesis of thyroid tumors and a hypothetical antiangiogenic activity of its soluble receptors.
  • Disequilibrium of the above-mentioned angiogenic factor concentrations is probably essential for the growth and progression of benign and malignant thyroid tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. Receptors, Vascular Endothelial Growth Factor / blood. Thyroid Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adult. Aged. Biopsy. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16350718.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


29. Pauzar B, Staklenac B, Loncar B: Fine needle aspiration biopsy of follicular thyroid tumors. Coll Antropol; 2010 Mar;34(1):87-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy of follicular thyroid tumors.
  • US-guided fine needle aspiration cytology is currently the best diagnostic tool for thyroid nodules.
  • The aim of this research was to make a detailed and objective determination of the morphological characteristics of cells in cytological smears in an attempt to distinguish benign from malignant follicular tumors.
  • The statistical analysis of cytological parameters has indicated that none of the cytological parameters alone is discriminating enough between non-tumor and tumor changes, or benign and malignant follicular thyroid nodules.
  • The analysis of age, sex, nodule size and ultrasound findings has not shown the correlation between any of these parameters with the malignant or benign follicular tumors.
  • The cytological analysis of the smears for patients with follicular tumors, in combination with clinical data and other diagnostic methods, contributes to more precise diagnostics, but is not sufficient for the differentiation between benign and malignant follicular tumors.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Biopsy, Fine-Needle / standards. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / pathology. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / pathology. Male. Middle Aged. Neoplasms / pathology. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432738.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Croatia
  •  go-up   go-down


30. Sassolas G, Hafdi-Nejjari Z, Remontet L, Bossard N, Belot A, Berger-Dutrieux N, Decaussin-Petrucci M, Bournaud C, Peix JL, Orgiazzi J, Borson-Chazot F: Thyroid cancer: is the incidence rise abating? Eur J Endocrinol; 2009 Jan;160(1):71-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer: is the incidence rise abating?
  • OBJECTIVE: The aim of the present study was to determine recent trends in thyroid cancer incidence rates and to analyze histopathological characteristics and geographical distribution.
  • METHODS: Histologically proven 5367 cases were collected over the period 1998-2006 in France from the Rhône-Alpes thyroid cancer registry.
  • They were fortuitously discovered after thyroidectomy for benign diseases in 64% of cases.
  • Histological marks of aggressiveness differed according to the size of the tumor.
  • Despite recent advances in diagnosis, 13% of tumors were diagnosed at advanced stage especially in men.
  • CONCLUSION: The present study suggests that the rise in thyroid cancer incidence is now abating.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952764.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


31. Kebebew E, Peng M, Reiff E, McMillan A: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer; 2006 Jun 15;106(12):2592-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.
  • BACKGROUND: Approximately 30% of fine-needle aspiration (FNA) biopsies of thyroid nodules are indeterminate, nondiagnostic, or suspicious.
  • The purpose of the current study was to determine the accuracy of novel candidate diagnostic markers to distinguish benign from malignant thyroid neoplasms, and to predict the extent of disease.
  • METHODS: A real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) assay of 6 novel candidate diagnostic and extent of disease marker genes (extracellular matrix protein 1 [ECM1]; transmembrane protease, serine 4 [TMPRSS4]; angiopoietin 2 [ANGPT2]; TIMP metallopeptidase inhibitor 1 [TIMP1]; ephrin-B2 [EFNB2], and epidermal growth factor receptor [EGFR]) was used in 126 thyroid tissues.
  • RESULTS: The levels of ECM1, TMPRSS4, ANGPT2, and TIMP1 mRNA expression were found to be independent diagnostic markers of malignant thyroid neoplasms.
  • In 31 thyroid nodule FNA biopsy samples, the scoring model had a sensitivity of 91.0%, a specificity of 95.0%, a positive predictive value of 92.9%, and a negative predictive value of 92.3%.
  • In 11 malignant thyroid nodule FNA samples, the extent of disease scoring model correctly identified 3 of 4 high-risk differentiated thyroid cancers and 7 of 7 low-risk differentiated thyroid cancers.
  • CONCLUSIONS: This novel multigene assay is an excellent diagnostic and extent of disease marker for differentiated thyroid cancer and would be a helpful adjunct to FNA biopsy of thyroid nodules.
  • [MeSH-major] Biomarkers, Tumor / genetics. Genes, Neoplasm / genetics. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / genetics
  • [MeSH-minor] Angiopoietin-2 / analysis. Angiopoietin-2 / genetics. Biopsy, Fine-Needle. Data Interpretation, Statistical. Diagnosis, Differential. Ephrin-B2 / analysis. Ephrin-B2 / genetics. Extracellular Matrix Proteins / analysis. Extracellular Matrix Proteins / genetics. Humans. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Messenger / genetics. ROC Curve. Receptor, Epidermal Growth Factor / analysis. Receptor, Epidermal Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Serine Endopeptidases / analysis. Serine Endopeptidases / genetics. Thyroid Diseases / diagnosis. Thyroid Diseases / genetics. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-1 / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16688775.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiopoietin-2; 0 / Biomarkers, Tumor; 0 / ECM1 protein, human; 0 / Ephrin-B2; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / transmembrane serine protease 2, human
  •  go-up   go-down


32. Gonçalves AP, Jorge CS, Resende JP, Villela JR, Soares MM, Ramos AV: [Benign hepatic cyst mimicking thyroid carcinoma metastasis]. Arq Bras Endocrinol Metabol; 2009 Aug;53(6):777-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign hepatic cyst mimicking thyroid carcinoma metastasis].
  • [Transliterated title] Cisto hepático benigno simulando metástase de carcinoma diferenciado de tireoide.
  • INTRODUCTION: The follow-up of differentiated thyroid carcinoma (DTC) for detecting persistent or recurrent disease is based on iodine whole body scan (WBS), the evaluation of the tumor marker thyroglobulin (Tg), the anti-thyroglobulin antibody (anti-Tg) and neck ultrasonography (US).
  • Well known false-positive causes of WBS include inflammatory processes, some non-thyroid tumors, kidney or even sebaceous cysts .
  • RESULTS: We enphasize the importance of recognizing benign liver cysts mimicking DTC metastasis.
  • [MeSH-major] Carcinoma, Papillary / radionuclide imaging. Cysts / radionuclide imaging. Iodine Radioisotopes. Liver Diseases / radionuclide imaging. Thyroid Neoplasms
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Thyroglobulin / therapeutic use. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893923.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


33. Krzysztof K, Wiktor B, Tadeusz Ł, Waldemar B, Magdalena K, Janusz D: Neuroendocrine tumours--analysis of own material--a nine--year retrospective study. Hepatogastroenterology; 2010 Mar-Apr;57(98):236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Neuroendocrine tumours are fairly rare neoplasms that require different treatments and have various prognoses.
  • The aim of this study was to present the author's observations of the histological tumor types, occurrence and its surgical treatment.
  • Ultrasonography, scintigraphy, computed tomography or magnetic resonance imaging of abdominal cavity, pelvis, thorax or neck--depend on the tumor localization--were done in every individual.
  • All cases were subjected to surgical procedure with an aim to resect the tumour completely.
  • In the study we have also 11 cases of medullary thyroid carcinomas.
  • In adrenal glands we observed 10 benign and 1 malignant pheochromocytoma (one bilateral female case with Multiple Endocrine Neoplasia type 2A).
  • The clinical manifestations of some neuroendocrine tumours are not specific, so it causes a lot of difficulties in early diagnosis and treatment.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Neuroendocrine Tumors / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583420.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


34. Hemerly JP, Bastos AU, Cerutti JM: Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur J Endocrinol; 2010 Nov;163(5):747-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
  • OBJECTIVES: To determine whether IDH1 had somatically acquired mutations in thyroid carcinomas.
  • DESIGN: Exons 4 and 6 of IDH1 were sequenced in a large panel of thyroid tumours (n=138) and compared with the patients normal DNA (n=26).
  • RESULTS: We identified four novel and two previously described non-synonymous variants in thyroid carcinomas, which were absent in benign tumours and paired normal thyroid.
  • Although IDH1 variants occurred at higher frequency in follicular thyroid carcinomas, follicular variant of papillary thyroid carcinoma (PTC) and undifferentiated thyroid carcinomas than the observed variants in classical PTC (15/72 vs 3/37), it was not significant (P=0.1).
  • CONCLUSION: IDH1-acquired genetic alterations are highly prevalent in thyroid carcinomas (16%).
  • Our findings not only extend our understanding of the molecular mechanism underlying pathogenesis of thyroid tumours, but also emphasize the biological differences between tumour types.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702649.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


35. Vorburger SA, Ubersax L, Schmid SW, Balli M, Candinas D, Seiler CA: Long-term follow-up after complete resection of well-differentiated cancer confined to the thyroid gland. Ann Surg Oncol; 2009 Oct;16(10):2862-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up after complete resection of well-differentiated cancer confined to the thyroid gland.
  • BACKGROUND: Papillary or follicular thyroid carcinomas exhibit a relatively benign course.
  • METHODS: Patients who underwent complete resection of well-differentiated thyroid carcinoma (WDTC) confined to the thyroid gland between 1972 and 1990 identified from a prospective database were assessed.
  • Review of histology was performed and extent of thyroid resection, postoperative therapy, and recognized prognostic factors but not lymphadenectomy were evaluated.
  • RESULTS: Of 2,867 patients, 213 had complete resection of WDTC confined to the thyroid gland.
  • DSS at 10 and 20 years was 81 and 69%, respectively, and correlated with age, histology, tumor size, radio-iodide ablation (RIA), and external beam irradiation (EBR) treatment.
  • Age, histology and postoperative therapy but not extent of thyroid resection determined DSS.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / surgery. Cell Differentiation. Thyroid Neoplasms / surgery. Thyroidectomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Feb;18(2):600 [20607419.001]
  • (PMID = 19655202.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Guida M, Mandato VD, Di Spiezio Sardo A, Di Carlo C, Giordano E, Nappi C: Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels. J Endocrinol Invest; 2005 Oct;28(9):827-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels.
  • BACKGROUND: Struma ovarii is the most common monodermal ovarian teratoma and consists mainly of thyroid tissue.
  • Only 5% of patients with this tumor have features of hyperthyroidism.
  • CASE: We describe a case of benign struma ovarii, presenting with the clinical features of an ovarian cancer: large complex pelvic mass, large amount of ascites and markedly elevated CA-125 serum levels.
  • [MeSH-major] CA-125 Antigen / blood. Graves Disease / etiology. Graves Disease / therapy. Ovarian Neoplasms / etiology. Ovarian Neoplasms / surgery. Struma Ovarii / etiology. Struma Ovarii / surgery

  • Genetic Alliance. consumer health - Graves' Disease.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. METHIMAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 1990 Feb;66(772):132-3 [2349185.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Feb;70(2):444-52 [1688867.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):405-8 [8522265.001]
  • [Cites] Clin Nucl Med. 1992 Jul;17 (7):577-8 [1638839.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1994 Jun 30;55(3):205-8 [7958166.001]
  • [Cites] Gynecol Oncol. 1989 Feb;32(2):224-7 [2910784.001]
  • [Cites] Eur J Endocrinol. 2004 Apr;150(4):431-7 [15080771.001]
  • [Cites] Gynecol Oncol. 2002 Aug;86(2):231-4 [12144834.001]
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):21-9 [7802134.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1996 Aug;36(3):372-3 [8883774.001]
  • [Cites] Cell Immunol. 1995 Apr 1;161(2):262-9 [7697737.001]
  • (PMID = 16370564.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-125 Antigen; 554Z48XN5E / Methimazole; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


37. Pavlov AV, Aleksandrov IuK, Beliakov IE, Korableva TV: [Morphological analysis of genetically damaged thyrocytes in nodular pathology of the thyroid gland]. Vestn Khir Im I I Grek; 2007;166(2):58-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphological analysis of genetically damaged thyrocytes in nodular pathology of the thyroid gland].
  • The smears of isolated thyrocytes with micronuclei taken from 25 patients with nodular pathology of the thyroid gland were investigated.
  • In all kinds of benign nodular pathology the number of micronucleated thyrocytes comes to 0.1-0.3%.
  • These values correspond to the spontaneous level of the content of aberrant thyrocytes in the thyroid gland of highly specialized cell populations.
  • In papillary carcinoma of the thyroid gland the average occurrence of micronucleated thyrocytes in the tumor nodule was about 0.4%.
  • In the tissue outside the tumor taken from both the same and the opposite lobes, the content of cells with micronuclei proved to be substantially higher--0.93-1%.
  • So, the marked increase of the concentration of genetically damaged cells in the thyroid parenchyma proved to be characteristic of the carcinoma of the thyroid gland.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology. Thyroid Nodule / genetics. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665578.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


38. Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ, LiVolsi VA: Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol; 2006;17(3):225-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis.
  • BACKGROUND: Several immunohistochemical markers have been used to aid in the diagnosis of follicular-derived lesions of the thyroid (FDLT).
  • In this study we analyze the diagnostic efficacy of an immunopanel of antibodies to cytokeratin-19 (CK19), galectin-3 (GAL-3), HBME-1, anti-MAP kinase (ERK), ret-oncoprotein (RET), and p16 using a tissue microarray consisting of both benign and malignant FDLT.
  • DESIGN: The study cohort consisted of 90 cases of FDLT (53 benign, 37 malignant) embedded in a microarray and immunostained with antibodies to CK19, Gal-3, HMBE-1, ERK, RET, and p16.
  • RESULTS: HMBE-1 was expressed in 70% of malignant and 10% of benign FDLT (p value: <0.0001).
  • CK19 and GAL-3 were positive in 70% and 73% of malignant lesions, respectively, and 34% of benign FDLT (p value 0.0005 and 0.0015, respectively).
  • ERK was positive in 4% of the benign and 32% of the malignant cases (p value 0.0002).
  • p16 was expressed in 2% and 46% of the benign and malignant lesions, respectively (p value 0.0001).
  • RET positivity was identified in 15% of the benign lesions and 27% of the malignant cases (p value 0.0016).
  • CONCLUSIONS: HBME-1, ERK, and p16 were more specific for malignancy, whereas CK19 and GAL-3 stained benign lesions with a higher frequency and were not specific for malignant FDLT.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Biomarkers, Tumor / analysis. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):165-6 [12162672.001]
  • [Cites] Ann Pathol. 2001 Feb;21(1):15-20 [11223556.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):216-22 [9930143.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):213-9 [8972756.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1166-71 [10534163.001]
  • [Cites] Histopathology. 2005 Oct;47(4):391-401 [16178894.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2185-93 [9827724.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1331-7 [1620547.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1373-6 [10571520.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):250-7 [14715858.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1139-45 [11014583.001]
  • [Cites] Cancer. 2000 Oct 25;90(5):307-11 [11038428.001]
  • [Cites] Pathol Res Pract. 2003;199(6):399-404 [12924440.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Rev Med Chil. 2004 Mar;132(3):279-84 [15376563.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):257-69 [16601293.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4294-302 [15240514.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):4011-8 [15840741.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):603-5; author reply 605-6 [12375649.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):541-6 [15529186.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2003 Dec;32(6):530-3 [14761598.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Histopathology. 2004 Jul;45(1):39-46 [15228442.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):710-3 [12033961.001]
  • [Cites] Oncogene. 1994 Feb;9(2):509-16 [8290261.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Lancet. 1994 Jul 23;344(8917):259 [7913169.001]
  • [Cites] Pol J Pathol. 2004;55(4):143-8 [15757201.001]
  • [Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Eur J Endocrinol. 2002 Oct;147(4):515-21 [12370115.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):319-22 [14974863.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):517-9 [14870775.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):70-4 [9894456.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4561-7 [12907632.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):1068-81 [15761501.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5152-8 [11701669.001]
  • [Cites] Am J Clin Pathol. 1999 Sep;112(3):311-6 [10478135.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):87-95 [15742329.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] Int J Surg Pathol. 2005 Jan;13(1):1-8 [15735849.001]
  • [Cites] J Lab Clin Med. 1994 Mar;123(3):331-7 [8133143.001]
  • [Cites] Histopathology. 2001 Jul;39(1):25-32 [11454041.001]
  • (PMID = 17308359.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Galectin 3; 0 / HBME-1 antigen; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


39. Chang YJ, Mittal V, Remine S, Manyam H, Sabir M, Richardson T, Young S: Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg; 2006 May;72(5):419-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma of the parathyroid is a rare malignancy that can be cured surgically if the proper diagnosis and treatment is given initially.
  • Our goal is to review the correlation between clinical and final histopathological findings that can arouse the suspicion of such malignancy and their true predictive value in the diagnosis.
  • Among 168 patients who underwent parathyroid excision, 14 (8.3%) had hyperplasia of the parathyroid, 121 (72%) had benign adenoma, 25 (14.8%) had other benign lesions, and 8 (4.7%) patients had primary carcinoma of the parathyroid confirmed by pathology.
  • Our mean serum calcium level was 11.57 mg/dL, which was lower than the mean level (12 mg/dL) for benign hyperparathyroidism.
  • The mean tumor size was 2.18 cm, smaller than the proposed for malignant criteria, and none of the eight patients (0%) had any symptoms of hypercalcemia at the time of diagnosis.
  • Seven of eight patients (87.5%) had frank signs of invasion together with other histological features, and two patients had associated papillary carcinoma of the thyroid.
  • Five patients from our series did not meet clinical criteria for malignancy (tumor size > 3 cm, palpable mass, and serum calcium > 14 mg/dL), but had undisputable histological findings (high mitotic pattern, fibrous trabeculae, capsular invasion, vascular invasion, and nodular involvement).
  • On the other hand, 17 patients with benign histology had tumors greater than 3 cm, and an additional 18 had palpable masses on physical examination.
  • The patients with diagnosis of parathyroid carcinoma, their kindred, and those with large adenomas may benefit from genetic screening for HRTP2 gene mutations in search of early detection of tumors suspicious for malignancy.
  • [MeSH-major] Parathyroid Neoplasms / diagnosis. Parathyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Adenoma / surgery. Aged, 80 and over. Calcium / blood. Female. Humans. Hyperparathyroidism / etiology. Male. Middle Aged. Mitosis. Neoplasm Invasiveness. Parathyroidectomy

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719197.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  •  go-up   go-down


40. Gessl A, Raber W, Staudenherz A, Becherer A, Koperek O, Hofmann A: Higher frequency of thyroid tumors in the right lobe. Endocr Pathol; 2010 Sep;21(3):186-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher frequency of thyroid tumors in the right lobe.
  • Recently, using ultrasonography, we observed that the right lobe usually is larger compared with the left thyroid lobe.
  • Since the higher cell number in a larger right lobe may confer a higher tumor risk, we investigated the location of benign and malignant lesions to test the hypothesis of a more frequent occurrence in this lobe.
  • In 1,001 consecutive patients with benign thyroid lesions, tumors more frequently occurred in the right lobe (+21.5%, p = 0.0022).
  • Furthermore, in 1,277 thyroid cancer patients with 1,302 thyroid cancers, the right lobe more often harbored the tumor initially (+22.9%, p = 0.0009).
  • Our data show a larger proportion of both benign and malignant tumors in the right thyroid lobe.
  • [MeSH-major] Adenoma / pathology. Carcinoma / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 1988 Apr;28(4):409-14 [3056637.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):681-7 [17005471.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jun;66(6):1240-6 [3259584.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Feb;56(2):260-3 [6822636.001]
  • [Cites] Br J Radiol. 1994 Jun;67(798):519-23 [8032803.001]
  • [Cites] Bull World Health Organ. 1997;75(2):95-7 [9185360.001]
  • [Cites] Acta Radiol. 2002 May;43(3):269-74 [12100323.001]
  • [Cites] Front Neuroendocrinol. 1997 Jul;18(3):354-81 [9237081.001]
  • [Cites] Surg Radiol Anat. 2006 Mar;28(1):25-32 [16374571.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Dec;129(6):505-10 [8109183.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10 ):1027-31 [14606557.001]
  • [Cites] Nuklearmedizin. 1981 Apr;20(2):64-71 [7243602.001]
  • [Cites] Hum Mol Genet. 2007 Feb 1;16(3):276-85 [17164259.001]
  • [Cites] Br J Surg. 1969 May;56(5):351-2 [5781045.001]
  • [Cites] Dtsch Med Wochenschr. 1981 Oct 9;106(41):1338-40 [7274082.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Oct;63(4):918-27 [3488999.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Clin Endocrinol (Oxf). 1978 Jun;8(6):483-6 [668154.001]
  • [Cites] Eur J Nucl Med. 1997 Dec;24(12 ):1470-8 [9391181.001]
  • [Cites] Dan Med Bull. 1991 Feb;38(1):87-9 [1878025.001]
  • [Cites] Dtsch Med Wochenschr. 1983 Sep 9;108(36):1355-8 [6884221.001]
  • (PMID = 20532675.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Porpora MG, Pallante D, Ferro A, Alò PL, Cosmi EV: Asymptomatic struma ovarii: a case report. Clin Exp Obstet Gynecol; 2005;32(3):197-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare ovarian neoplasm.
  • This tumor is generally benign, although malignant transformation has been reported.
  • The preoperative diagnosis is generally difficult.
  • Thyroid hormones may be produced and in a few cases asymptomatic women may develop definitive clinical hypothyroidism after resection of struma ovarii.
  • The pathologic diagnosis was struma ovarii.
  • The postoperative period was uneventful and her thyroid function remained normal.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Struma Ovarii / diagnosis. Struma Ovarii / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433164.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Giovanella L, Ceriani L, Ghelfo A, Maffioli M: Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. Int J Biol Markers; 2008 Jan-Mar;23(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland.
  • Cytokeratin 19 (CK19) is an acidic protein of 40 kDa that is part of the cytoskeleton of epithelial cells and is highly expressed by differentiated thyroid carcinomas, mainly of the papillary subtype.
  • The present study was planned to assess the serum expression of Cyfra 21.1 in patients with benign thyroid nodules and thyroid malignancies.
  • We enrolled 135 patients with histologically proven benign thyroid nodules (n=79) and thyroid carcinomas (n=56).
  • No differences were found in serum Cyfra 21.1 levels between patients with benign nodules and patients with carcinomas.
  • When thyroid malignancies were subdivided according to tumor histology, serum Cyfra 21.1 increased significantly from classical differentiated thyroid carcinomas (papillary or follicular) to less differentiated or undifferentiated carcinomas (poorly differentiated or anaplastic).
  • These pathways characterized anaplastic and poorly differentiated thyroid carcinoma but not classical forms of differentiated thyroid carcinoma.
  • Consequently, Cyfra 21.1 may be regarded as a circulating marker of poorly differentiated and anaplastic thyroid carcinoma.
  • Additionally, a role of Cyfra 21.1 as a dedifferentiation marker in patients with classical differentiated thyroid carcinomas may be postulated and should be explored by further focused studies.
  • [MeSH-major] Antigens, Neoplasm / blood. Keratin-19 / blood. Keratins / blood. Thyroid Neoplasms / blood. Thyroid Nodule / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / pathology. Adolescent. Adult. Aged. Apoptosis. Biomarkers, Tumor / blood. Carcinoma, Papillary / blood. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Peptide Fragments / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409152.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / Peptide Fragments; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


43. Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T, Kakudo K: Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors. Pathol Int; 2006 May;56(5):240-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors.
  • Thyroid transcription factor 1 (TTF1), thyroid transcription factor 2 (TTF2) and paired box gene 8 (Pax8) are demonstrated to play a crucial role for the differentiation and organogenesis of thyroid follicular cells.
  • Their roles in thyroid carcinogenesis are not very clear.
  • Because dedifferentiation is a common process in thyroid carcinogenesis, thyroid-specific transcription factors seem also to be involving in thyroid carcinogenesis.
  • The purpose of the present paper was to investigate their expression in a broad spectrum of follicular cell tumors in different degrees of differentiation, from well-differentiated benign follicular adenoma to anaplastic carcinoma.
  • Results of immunohistochemical staining showed that nuclear localization of these transcription factors was gradually decreased corresponding to the progressive dedifferentiation of thyroid tumors.
  • In conclusion, abnormal expression of TTF1, TTF2 and Pax8 was closely related to thyroid tumorigenesis.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. DNA-Binding Proteins / metabolism. Immunohistochemistry / methods. Thyroid Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Adenosine Triphosphatases. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Humans. Paired Box Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16669872.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / TTF1 protein, human; 0 / Transcription Factors; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / TTF2 protein, human
  •  go-up   go-down


44. Kirschner LS, Kusewitt DF, Matyakhina L, Towns WH 2nd, Carney JA, Westphal H, Stratakis CA: A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res; 2005 Jun 1;65(11):4506-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues.
  • Carney complex is an autosomal dominant neoplasia syndrome characterized by spotty skin pigmentation, myxomatosis, endocrine tumors, and schwannomas.
  • Although genotype-specific cardiac and adrenal lesions were not seen, benign and malignant thyroid neoplasias were observed in older mice.
  • Genetic analysis indicated that allelic loss occurred in a subset of tumor cells, suggesting that complete loss of Prkar1a plays a key role in tumorigenesis.
  • These observations confirm the identity of PRKAR1A as a tumor suppressor gene with specific importance to cyclic AMP-responsive tissues and suggest that these mice may be valuable tools not only for understanding endocrine tumorigenesis but also for understanding inherited predispositions for schwannoma formation.
  • [MeSH-major] Cyclic AMP / physiology. Disease Models, Animal. Multiple Endocrine Neoplasia / genetics. Neurilemmoma / genetics. Proteins / genetics
  • [MeSH-minor] Alleles. Animals. Bone Neoplasms / enzymology. Bone Neoplasms / genetics. Bone Neoplasms / pathology. Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. Female. Genes, Tumor Suppressor. Genetic Predisposition to Disease. Male. Mice. Osteoblasts / cytology. Osteoblasts / physiology. Schwann Cells / cytology. Schwann Cells / physiology. Syndrome. Thymus Gland / cytology. Thymus Gland / physiology. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930266.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16058; United States / NICHD NIH HHS / HD / HD01323
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / Prkar1a protein, mouse; 0 / Proteins; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


45. Xu MR, Chen Y, Zhou SR, Chi MM, Chen SL, Liu LY: [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance]. Zhonghua Zhong Liu Za Zhi; 2009 May;31(5):356-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance].
  • OBJECTIVE: To investigate the mRNA expressions of RASSF1A, Galectin-3 and TPO in papillary thyroid carcinoma and some other thyroid benign lesions, and evaluate their diagnostic significance.
  • METHODS: Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the mRNA expression of RASSF1A, galectin-3 and TPO in the samples from 73 cases, including 23 cases with papillary thyroid cancer, 16 with nodular goiter, 29 with thyroid adenoma and 5 with Hashimoto's disease.
  • RESULTS: A statistically significant difference in the mRNA expression of RASSF1A, Galectin-3 and TPO was observed between papillary thyroid carcinoma and follicular benign lesions (P<0.05).
  • However, there was no significant difference among various kinds of benign lesions (P>0.05).
  • A negative correlation of the expression of RASSF1A and Galectin-3 mRNA was found between thyroid benign lesions and malignant ones (P = 0.000).
  • While the mRNA expression of RASSF1A and TPO was positively correlated between benign and malignant lesions (P = 0.028).
  • CONCLUSION: Loss of expression of RASSF1A and TPO mRNA but high expression of Galectin-3 mRNA in papillary thyroid carcinoma are common.
  • Therefore, the products of these three genes may be closely related to the development of thyroid papillary carcinoma, and may be used as useful markers in differential diagnosis of papillary thyroid carcinoma from the benign lesions.
  • [MeSH-major] Autoantigens / metabolism. Carcinoma, Papillary / metabolism. Galectin 3 / metabolism. Iodide Peroxidase / metabolism. Iron-Binding Proteins / metabolism. Thyroid Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Goiter, Nodular / genetics. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Hashimoto Disease / genetics. Hashimoto Disease / metabolism. Hashimoto Disease / pathology. Humans. Male. Middle Aged. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799084.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Iron-Binding Proteins; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; EC 1.11.1.7 / TPO protein, human; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


46. Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M: Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer; 2005 Jun;12(2):305-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
  • The distinction of benign from malignant follicular thyroid neoplasms remains a difficult task in diagnostic fine-needle aspiration cytology, and some discrepant results have been reported for the individual immunocytochemical markers of malignancy proposed so far.
  • The aim of this study was to test if the combined use of a panel of markers could improve the diagnostic accuracy in the preoperative cytological evaluation of 'follicular neoplasms' in an attempt to reduce the number of thyroidectomies performed for benign lesions.
  • The immunocytochemical expression of galectin-3, HBME-1, thyroperoxidase, cytokeratin-19 and keratan-sulfate was retrospectively analyzed in 125 consecutive fine-needle aspiration samples (cell blocks) of indeterminate diagnoses of 'follicular thyroid neoplasm', and compared with their corresponding surgical specimens, including 33 follicular carcinomas, 42 papillary carcinomas and 50 follicular adenomas.
  • Our data showed that, as compared with the use of single markers, the sequential combination of two markers represents the most accurate immunohistochemical panel in managing patients with a fine-needle aspiration biopsy diagnosis of 'follicular neoplasms', especially in otherwise controversial categories such as oncocytic tumours.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Biomarkers, Tumor / analysis. Immunohistochemistry. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947105.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


47. Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y: Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther; 2010 Aug;9(8):2208-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
  • Anaplastic thyroid carcinomas are deadly tumors that are highly invasive, particularly into the bones.
  • Although oncogenic Ras can transform thyroid cells into a severely malignant phenotype, thyroid carcinomas do not usually harbor ras gene mutations.
  • Therefore, it is not known whether chronically active Ras contributes to thyroid carcinoma cell proliferation, although galectin-3 (Gal-3), which is strongly expressed in thyroid carcinomas but not in benign tumors or normal glands, is known to act as a K-Ras chaperone that stabilizes and drives K-Ras.GTP nanoclustering and signal robustness.
  • Here, we examined the possibility that thyroid carcinomas expressing high levels of Gal-3 exhibit chronically active K-Ras.
  • Using cell lines representing three types of malignant thyroid tumors--papillary, follicular, and anaplastic--we investigated the possible correlation between Gal-3 expression and active Ras content, and then examined the therapeutic potential of the Ras inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS; Salirasib) for thyroid carcinoma.
  • Thyroid carcinoma cells strongly expressing Gal-3 showed high levels of K-Ras.GTP expression, and K-Ras.GTP transmitted strong signals to extracellular signal-regulated kinase.
  • FTS disrupted interactions between Gal-3 and K.Ras, strongly reduced K-Ras.GTP and phospho-extracellular signal-regulated kinase expression, and enhanced the expression of the cell cycle inhibitor p21 as well as of the thyroid transcription factor 1, which is involved in thyroid cell differentiation.
  • FTS also inhibited anaplastic thyroid carcinoma cell proliferation in vitro and tumor growth in nude mice.
  • We conclude that wild-type K-Ras.GTP in association with Gal-3 contributes to thyroid carcinoma malignancy and that Ras inhibition might be a useful treatment strategy against these deadly tumors.
  • [MeSH-major] Cell Differentiation. Galectin 3 / metabolism. Proto-Oncogene Proteins / metabolism. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology. ras Proteins / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / metabolism. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Models, Animal. Down-Regulation / drug effects. Enzyme Activation / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Farnesol / analogs & derivatives. Farnesol / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Guanosine Triphosphate / metabolism. Humans. Mice. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Protein Transport / drug effects. Salicylates / pharmacology. Signal Transduction / drug effects. Transcription Factors / genetics. Transcription Factors / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FARNESOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • (PMID = 20682656.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Galectin 3; 0 / KRAS protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Salicylates; 0 / Transcription Factors; 0 / farnesylthiosalicylic acid; 0 / thyroid nuclear factor 1; 4602-84-0 / Farnesol; 86-01-1 / Guanosine Triphosphate; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


48. Wang JD, Deng XC, Jin XJ, Zhou C, Zhang C, Xie M, Zhou JQ, Qian MF: [Clinical research on 2228 cases of thyroid gland tumors]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Apr;40(4):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research on 2228 cases of thyroid gland tumors].
  • OBJECTIVE: To discuss outcome of thyroid tumor patients treated with surgery.
  • These patients of thyroid tumors from 1992-2004 (2072 cases of benign thyroid diseases and 156 cases of thyroid carcinoma) were recruited.
  • (1) Benign thyroid tumors with near-total thyroidectomy including 1761 thyroid adenoma, 207 nodular goiter and 104 Hashimoto thyroiditis, the incidence of recurrent laryngeal nerve paralysis was 0.2%, 55 cases (2.6%) received secondary surgery.
  • All the patients have no hypocalcemia or hemorrhage after operation. (2) Eighty-one cases of papillary carcinoma of the thyroid ( > 1 cm) and 60 cases of microcarcinoma.
  • Unilateral thyroidectomy, contralateral near-total thyroidectomy and ipsilateral modified neck dissection were performed in unilateral papillary carcinoma of thyroid.
  • Among the 9 cases of follicular carcinoma of thyroid, 7 were performed of near-total thyroidectomy without neck dissection, others were the same as papillary carcinoma.
  • Bilateral total thyroidectomy and bilateral modified neck dissection were performed in 2 cases of the medullary thyroid cancer and 1 case of the undifferentiated thyroid cancer.
  • There is no relapse or metastases in 60 cases of papillary thyroid microcarcinoma.
  • The 5-year survival was 100.0%, 1 cases occurred recurrent laryngeal nerve paralysis in thyroid cancer.
  • Eight case relapsed in 156 cases of thyroid carcinoma,3 cases died.
  • CONCLUSION: The correct surgical management for the patients with thyroid tumor should benefit for the prognosis and reduce the complications and the recurrence of the operation.
  • [MeSH-major] Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008266.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Raggio E, Camandona M, Solerio D, Martino P, Franchello A, Orlandi F, Gasparri G: The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions. J Endocrinol Invest; 2010 Jun;33(6):378-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic accuracy of the immunocytochemical markers in the pre-operative evaluation of follicular thyroid lesions.
  • MATERIALS AND METHODS: We retrospectively evaluated 100 patients suffering from thyroid nodular disease submitted to thyroidectomy from 2006 to 2007 in our Institution.
  • The GAL3 expression in neoplastic and benign lesions was significantly different (GAL3+ in 16 out of 29 neoplastic lesions, GAL3+ 0 out of 31 benign lesions, p<0.01).
  • CONCLUSIONS: Based on the data from our experience, the patients with a cytological diagnosis of GAL3 positive follicular neoformation should be referred for surgery without any further immunocytological testing.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Galectin 3 / analysis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Biomarkers / analysis. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Diagnostic Errors. Female. Gene Expression. Humans. Keratin-19 / biosynthesis. Male. Middle Aged. Predictive Value of Tests. Preoperative Care. Retrospective Studies. Sensitivity and Specificity. Thyroid Gland / chemistry. Thyroid Gland / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Langenbecks Arch Surg. 2004 Jun;389(3):193-7 [15107999.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):950; author reply 950-1 [12574240.001]
  • [Cites] Cancer Lett. 2003 Mar 10;191(2):223-7 [12618337.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):663-710 [8608777.001]
  • [Cites] Diagn Cytopathol. 2002 Jan;26(1):41-4 [11782086.001]
  • [Cites] J Pathol. 1997 Jan;181(1):80-6 [9072007.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] World J Surg. 1994 Jul-Aug;18(4):529-34 [7725740.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):579-83 [12708901.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Endocr Pathol. 2001 Fall;12(3):255-7 [11740046.001]
  • [Cites] Acta Cytol. 1997 May-Jun;41(3):687-91 [9167684.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Am J Med. 1994 Aug;97(2):152-7 [8059781.001]
  • (PMID = 19625759.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19
  •  go-up   go-down


50. Gartner W, Mineva I, Daneva T, Baumgartner-Parzer S, Niederle B, Vierhapper H, Weissel M, Wagner L: A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients. Hum Genet; 2005 Jul;117(2-3):143-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients.
  • To investigate endocrine tumor tissue characteristic RET proto-oncogene expression, we performed quantitative RT-PCR, Northern blot and Southern blot analyses of benign and malignant endocrine-derived tissues.
  • In addition, the presence of a 3'-terminally truncated RET proto-oncogene mRNA variant in benign and malignant thyroid neoplasias, as well as in a pheochromocytoma, an ovarian carcinoma and a medullary thyroid carcinoma, is demonstrated.
  • Heterozygous genotypes were found in a significantly higher percentage in samples derived from endocrine tumor patients when compared with those from healthy control subjects.
  • Analysis of DNA derived from varying regions within individual anaplastic thyroid carcinomas revealed an allele 1/allele 2 switch of the RFLP banding pattern, indicating loss of heterozygosity at the RET proto-oncogene locus.
  • A heterozygous genotype for this polymorphism is found in a considerable number of endocrine tumor patients.
  • [MeSH-major] 3' Untranslated Regions / genetics. Endocrine Gland Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Loss of Heterozygosity / genetics. Oncogene Proteins / genetics. Polymorphism, Restriction Fragment Length. Receptor Protein-Tyrosine Kinases / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1992;61:419-40 [1353951.001]
  • [Cites] Hum Genet. 1996 Mar;97(3):299-303 [8786068.001]
  • [Cites] Dev Biol. 2003 Feb 15;254(2):262-76 [12591246.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):380-3 [8114940.001]
  • [Cites] Mol Cell Neurosci. 1999 May;13(5):313-25 [10356294.001]
  • [Cites] Oncogene. 1995 Nov 16;11(10):2039-45 [7478523.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Pathol. 1994 Mar;172(3):255-60 [8195928.001]
  • [Cites] Nucleic Acids Res. 1996 Jun 15;24(12):2288-94 [8710498.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):785-9 [8657281.001]
  • [Cites] Oncogene. 1995 Apr 6;10(7):1377-83 [7731689.001]
  • [Cites] Oncogene. 1999 Jul 1;18(26):3919-22 [10445857.001]
  • [Cites] J Mol Med (Berl). 2003 Jul;81(7):411-9 [12811413.001]
  • [Cites] Science. 1995 Jan 20;267(5196):381-3 [7824936.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2845-9 [10850426.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):789-93 [8657282.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3445-8 [10918602.001]
  • [Cites] Oncogene. 1988 Nov;3(5):571-8 [3078962.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):430-5 [11912494.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):377-8 [8114938.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2979-85 [8187085.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Jun 30;153(3):1290-5 [3390185.001]
  • [Cites] Hum Genet. 1995 Jul;96(1):27-32 [7607650.001]
  • [Cites] Nucleic Acids Res. 1990 Dec 25;18(24):7472 [1979682.001]
  • [Cites] Oncogene. 1990 Jan;5(1):97-102 [2181380.001]
  • [Cites] Biochimie. 1999 Apr;81(4):397-402 [10401675.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1369-73 [10022819.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2575-82 [8361767.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):375-6 [7906866.001]
  • [Cites] Cell. 1990 Feb 23;60(4):557-63 [2406025.001]
  • [Cites] J Cell Physiol. 2003 May;195(2):168-86 [12652644.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):525-30 [9467569.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):380-93 [10458257.001]
  • [Cites] Cell. 1985 Jun;41(2):349-59 [2580642.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):1025-32 [12963982.001]
  • [Cites] Oncogene. 1990 Oct;5(10):1595-8 [1701232.001]
  • [Cites] Adv Anat Pathol. 2001 Nov;8(6):345-54 [11707626.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5590-7 [11114739.001]
  • (PMID = 15841388.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


51. Jiang B, Wu GP, Zhao YJ, Wang SC: Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol; 2008 Dec;36(12):849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate diagnostic utility of thyroid transcription factor 1 (TTF-1) mRNA in pleural effusions (PEs) of patients with lung cancer, especially primary pulmonary adenocarcinoma (PPA).
  • Transcription levels of TTF-1 were detected by reverse transcription polymerase chain reaction (RT-PCR) in PEs of patients with lung cancer (56 cases) and with lung benign diseases (44 cases).
  • The expression rate of TTF-1 mRNA was significantly higher in PEs of patients with lung cancer (73.2%) than with benign lung diseases (0%).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Nuclear Proteins / genetics. Pleural Effusion, Malignant / diagnosis. RNA, Messenger / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18855882.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


52. Fukushima M, Ito Y, Hirokawa M, Miya A, Kobayashi K, Akasu H, Shimizu K, Miyauchi A: Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule. World J Surg; 2009 May;33(5):963-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent prognosis of patients with nonhereditary medullary thyroid carcinoma with ultrasonographic findings of follicular tumor or benign nodule.
  • BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for only 1.4% of all thyroid malignancies in Japan.
  • Generally, MTC shows ultrasonographic findings typical of thyroid carcinoma.
  • However, in our experience, some MTC may be diagnosed as a follicular tumor or a benign nodule on ultrasonography because ultrasonographic findings of malignancy are lacking.
  • Of these patients, 54 were diagnosed as having thyroid carcinoma (malignant, or M-type) but the remaining 23 were diagnosed as having follicular tumor or benign nodule (benign, or B-type) on ultrasonography.
  • RESULTS: Clinically apparent lateral node metastasis, extrathyroid extension, and extranodal tumor extension were observed in 37%, 17%, and 11% of M-type patients, respectively, but none of the B-type patients showed any of these features.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnostic imaging. Carcinoma, Medullary / diagnostic imaging. Thyroid Neoplasms / diagnostic imaging
  • [MeSH-minor] Adult. Aged. Calcitonin / blood. Carcinoembryonic Antigen / blood. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Survival Analysis. Thyroidectomy. Ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Apr 15;77(8):1556-65 [8608543.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):415-9 [15837050.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):85-93 [17609406.001]
  • [Cites] Nature. 1993 Jun 3;363(6428):458-60 [8099202.001]
  • [Cites] Clin Investig. 1993 Jan;71(1):7-12 [8095831.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):111-8 [11356339.001]
  • [Cites] Medicine (Baltimore). 1984 Nov;63(6):319-42 [6503683.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1305-11 [15517484.001]
  • [Cites] Am J Clin Pathol. 1978 Oct;70(4):587-94 [360824.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):808-14 [1643612.001]
  • [Cites] Laryngoscope. 2005 Aug;115(8):1445-50 [16094121.001]
  • [Cites] Thyroid. 2007 Dec;17 (12 ):1269-76 [17988196.001]
  • [Cites] Ann Surg. 2007 Nov;246(5):815-21 [17968174.001]
  • [Cites] Mayo Clin Proc. 1992 Oct;67(10):934-40 [1434853.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1139-48 [10699905.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):806-16 [2448025.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1367-72 [11038208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579-83 [7906417.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):56-60 [15999359.001]
  • [Cites] Thyroid. 2007 Jul;17(7):635-8 [17696833.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):880-7; discussion 887-8 [10363903.001]
  • [Cites] Diagn Cytopathol. 2000 Jun;22(6):351-8 [10820528.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):132-8 [8988737.001]
  • [Cites] World J Surg. 2006 Jan;30(1):84-90 [16369705.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] World J Surg. 2009 Jan;33(1):58-66 [19005720.001]
  • [Cites] Thyroid. 1996 Aug;6(4):305-10 [8875751.001]
  • [Cites] Endocr J. 2004 Oct;51(5):453-6 [15516777.001]
  • [Cites] World J Surg. 1996 Sep;20(7):848-53; discussion 853 [8678961.001]
  • (PMID = 19198929.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 9007-12-9 / Calcitonin
  •  go-up   go-down


53. Randolph GW, Kamani D: [Laryngoscopy in patients undergoing thyroidectomy]. Vestn Khir Im I I Grek; 2007;166(3):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a group of 365 patients undergoing thyroidectomy, the group of 21 patients with invasive thyroid malignancy was compared with 344 patients with benign thyroid disease or noninvasive cancers.
  • It was shown that the method of indirect laryngoscopic examination was a simple and efficient method for detection of vocal cord paralysis and for the assessment of involvement of the surrounding tissues by the tumor.
  • For the preoperative diagnosis of invasion of the recurrent nerve area such criteria as changed voice, results of CT and MRT were shown to be insufficiently reliable.
  • [MeSH-major] Laryngoscopy / methods. Thyroid Diseases / diagnosis. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18050638.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


54. Lee JM, Kim JW, Song JY, Lee JK, Lee NW, Kim SH, Lee KW: Adenocarcinoma arising in mature cystic teratoma: a case report. J Gynecol Oncol; 2008 Sep;19(3):199-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign cystic teratoma is recognized as one of the most common tumors in women during the reproductive age and frequently is treated by pelviscopic operation.
  • Malignant transformation of a benign cystic teratoma is a rare event, and adenocarcinoma is extremely rare, and distinguishing this malignant change from benign disease preoperatively is nearly impossible even by the use of radiological imaging or various tumor markers.
  • We present a case with thyroid papillary carcinoma of follicular variant arising from mature cystic teratoma removed by laparoscopic salpingo-oophorectomy followed by staging laparotomy.
  • We briefly reviewed literatures with regard to malignant transformation of a benign cystic teratoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):318-20 [17652549.001]
  • [Cites] Pathol Res Pract. 2006;202(7):531-5 [16713128.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):140-4 [16445624.001]
  • [Cites] Obstet Gynecol Surv. 1957 Dec;12(6):793-830 [13493921.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1326-33 [9788856.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2249-55 [9610706.001]
  • [Cites] Obstet Gynecol Surv. 2000 Dec;55(12):738-45 [11128910.001]
  • [Cites] Gynecol Oncol. 1992 Jun;45(3):248-53 [1319383.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1988 Dec;29(4):329-38 [3229546.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):597-9 [15297213.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):139-43 [14720146.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):338-41 [12893196.001]
  • [Cites] Arch Gynecol Obstet. 2002 Dec;267(2):107-9 [12439559.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jun;117(6):647-9 [8503739.001]
  • (PMID = 19471568.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676465
  • [Keywords] NOTNLM ; Adenocarcinoma / Malignant transformation / Mature cystic teratoma / Tumor marker
  •  go-up   go-down


55. Wang X, Koch S: Positron emission tomography/computed tomography potential pitfalls and artifacts. Curr Probl Diagn Radiol; 2009 Jul-Aug;38(4):156-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the recent use of 18-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) for tumor staging and treatment response, it is important to recognize many pitfalls, artifacts, and benign uptakes that are commonly encountered.
  • Normal physiology can explain many regions of increased FDG activity, as well as incidental benign tumors and benign metabolic conditions.
  • Recognition of characterization of benign causes and physiologic variants for FDG uptake are discussed to avoid improper characterization as a malignancy.
  • Also presented is the rationale for expected, benign uptake in various metabolic diseases, as well as pharmacologic methods for decreasing the artifacts caused by metabolic diseases.
  • PET/computed tomographic evaluation of the thyroid, thymus, adrenal adenomas, uterus and ovaries, infection/inflammatory changes, and postradiation/chemotherapy changes are also discussed, with expected normal changes, as well as pitfalls and artifacts.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464586.001).
  • [ISSN] 1535-6302
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 44
  •  go-up   go-down


56. Meyer EL, Wagner MS, Maia AL: [Iodothyronine deiodinases expression in thyroid neoplasias]. Arq Bras Endocrinol Metabol; 2007 Jul;51(5):690-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Iodothyronine deiodinases expression in thyroid neoplasias].
  • [Transliterated title] Expressão das iodotironinas desiodases nas neoplasias tireoidianas.
  • The iodothyronine deiodinases constitute a family of selenoenzymes that catalyze the removal of iodine from the outer ring or inner ring of the thyroid hormones.
  • The activating enzymes, deiodinases type I (D1) and type II (D2), are highly expressed in normal thyroid gland.
  • Benign or malignant neoplastic transformation of the thyroid cells is associated with changes on the expression of these enzymes, suggesting that D1 or D2 can be markers of cellular differentiation.
  • Abnormalities on the expression of both enzymes and also of the deiodinase type III (D3), that inactivates thyroid hormones, have been found in other human neoplasias.
  • So far, the mechanism or implications of these findings on tumor pathogenesis are not well understood.
  • Nevertheless, its noteworthy that abnormal expression of D2 can cause thyrotoxicosis in patients with metastasis of follicular thyroid carcinoma and that increased D3 expression in large hemangiomas causes severe hypothyroidism.
  • [MeSH-major] Carcinoma, Papillary / enzymology. Iodide Peroxidase / metabolism. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Gene Expression Regulation, Enzymologic / physiology. Hemangioma / enzymology. Hemangioma / genetics. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. Thyroid Gland / enzymology. Thyroxine / metabolism. Triiodothyronine / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17891232.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 06LU7C9H1V / Triiodothyronine; EC 1.11.1.- / iodothyronine deiodinase type I; EC 1.11.1.- / iodothyronine deiodinase type II; EC 1.11.1.- / iodothyronine deiodinase type III; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
  • [Number-of-references] 86
  •  go-up   go-down


57. Ponikiewska D, Szcześniak-Kłusek B, Stobiecka E, Jaworska M, Lange D: [Oxyphilic and follicular thyroid tumors--the correlation between the cytopathologic diagnosis and the histopathologic examination]. Endokrynol Pol; 2006;57 Suppl A:7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxyphilic and follicular thyroid tumors--the correlation between the cytopathologic diagnosis and the histopathologic examination].
  • INTRODUCTION: Fine needle aspiration biopsy (FNAB) of the thyroid nodules generally allows to make the diagnosis and to choose the proper clinical management.
  • In about 10% of cases cytopathologic features do not differentiate unequivocally benign and malignant lesions.
  • In these cases the cytopathologic diagnosis of follicular tumor (FT) or oxyphilic tumor (OT) is most often made.
  • MATERIALS AND METHODS: From 2001 to 2002 in our Department of Pathology the cytopathologic diagnosis of FT and OT was made in 102 and 25 cases respectively.
  • RESULTS: Histopathological diagnosis of neoplasm was made in 48.7% (19/39) FT and 42% (8/19) OT.
  • CONCLUSIONS: These results show how difficult the diagnostics of follicular lesions in FNAB could be because of the frequent overlapping of the cytological features of benign and malignant lesions.
  • Diagnosis of follicular tumor does not mean carcinoma.
  • The use of follicular/ oxyphilic tumor in cytological diagnostic instead of follicular neoplasm seems more advisable.
  • [MeSH-major] Adenocarcinoma / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091450.001).
  • [ISSN] 2299-8306
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


58. Kawano Y, Tamura A, Goto Y, Shinozaki K, Zaizen H, Kadota J: Incidental detection of cancers and other non-cardiac abnormalities on coronary multislice computed tomography. Am J Cardiol; 2007 Jun 1;99(11):1608-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancers were found in 7 patients (1.13%) on the multislice computed tomographic images, including 4 lung cancers (0.65%), 2 thyroid cancers (0.32%), and 1 hepatic cancer (0.16%).
  • In addition, nonmalignant abnormalities (nodules, tumors, or lymphadenopathies) were also found in 142 patients (23.01%), consisting of 58 postinflammatory lung nodules (9.40%), 49 hepatic cysts or hemangiomas (7.94%), 18 benign thyroid tumors (2.92%), 12 mediastinal lymphadenopathies (1.94%), 4 benign mammary gland tumors (0.65%), and 1 esophageal submucosal tumor (0.16%).
  • [MeSH-major] Coronary Artery Disease / radiography. Incidental Findings. Neoplasms / pathology. Neoplasms / radiography. Tomography, X-Ray Computed


59. Führer D, Schmid KW: [Benign thyroid nodule or thyroid cancer?]. Internist (Berl); 2010 May;51(5):611-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign thyroid nodule or thyroid cancer?].
  • Thyroid nodular disease is highly frequent and affects 20-23% of the adult population in Germany.
  • Differential diagnosis of thyroid nodules is directed at exclusion of thyroid autonomy and thyroid cancer.
  • Besides the patient's history and clinical examination, laboratory investigations (TSH-level, calcitonin screening), functional (scintiscan) and morphological imaging (ultrasound, in rare cases also CT without contrast media and MRI), as well as fine needle aspiration biopsy are useful tools in the differential diagnosis.
  • In the past years, major advances have been made in the understanding of the molecular pathogenesis of thyroid tumors.
  • This has led to the possibility of a molecular classification of thyroid tumors and may have prognostic as well as therapeutic impact.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / blood. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pract. 2006 Jan-Feb;12(1):63-102 [16596732.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1748-51 [19276237.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80 [16365291.001]
  • [Cites] Nuklearmedizin. 2003 Oct;42(5):181-9 [14571314.001]
  • [Cites] Histopathology. 2010 Apr;56(5):632-40 [20459574.001]
  • [Cites] Endocr Rev. 2007 May;28(3):322-38 [17353294.001]
  • [Cites] Thyroid. 2003 Aug;13(8):803-10 [14558922.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8 [16478817.001]
  • [Cites] Endocr Rev. 2005 Jun;26(4):504-24 [15615818.001]
  • [Cites] Dtsch Med Wochenschr. 2005 Aug 5;130(31-32):1831-6 [16052449.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1092-100 [14652809.001]
  • [Cites] Radiology. 2005 Dec;237(3):794-800 [16304103.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):957-77 [18045949.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):891-900 [17289376.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):475-81 [19370508.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] Eur J Endocrinol. 2006 Jun;154(6):787-803 [16728537.001]
  • [Cites] Virchows Arch. 2009 Jul;455(1):21-33 [19543912.001]
  • [Cites] Pathologe. 2003 Sep;24(5):357-72 [12961024.001]
  • [Cites] Int J Surg Pathol. 2000 Jul;8(3):181-183 [11493987.001]
  • [Cites] Mol Endocrinol. 2002 May;16(5):903-11 [11981026.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Aug;94(8):2970-4 [19491231.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):376-82 [20029416.001]
  • [Cites] Horm Metab Res. 2009 Jun;41(6):482-7 [19370505.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Feb;117(2):145-53 [2837884.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Thyroid. 2004 Nov;14 (11):926-32 [15671771.001]
  • [Cites] Thyroid. 2009 Jun;19(6):565-612 [19469690.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):713-20 [17893690.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1390-3 [18198227.001]
  • [Cites] Nuklearmedizin. 2003 Jun;42(3):120-2 [12802476.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1600-8 [18270258.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):385-93 [16506015.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):531-8 [2408737.001]
  • [Cites] Histopathology. 2008 Apr;52(5):623-30 [18370959.001]
  • (PMID = 20405098.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


60. Tsurubuchi T, Yamamoto T, Tsukada Y, Matsuda M, Nakai K, Matsumura A: Meningioma associated with Werner syndrome--case report--. Neurol Med Chir (Tokyo); 2008 Oct;48(10):470-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten months later, the right convexity tumor was removed because follow-up MR imaging detected tumor growth.
  • The histological diagnosis was transitional meningioma.
  • Most meningiomas associated with Werner syndrome are benign, but are sometimes complicated with extracranial tumors such as sarcoma, thyroid carcinoma, and others.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Werner Syndrome / complications


61. Keita M, Kampo MI, Timbo SK, Traoré CB, Diallo M, Doumbia-Singaré K, Ag Mohamed A: [Morbidity of the tumours of the sphere head and neck in Bamako]. Mali Med; 2009;24(3):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Morbidite par tumeurs de la sphere tete et cou a Bamako.
  • Among the 60 cases, 24 tumours (40%) were malign and 36 were benign.
  • Goiter was the most found benign tumor according to the results of the hystology analysis.
  • Other malign tumors have been found: nose and sinusal cancers and thyroid carcinoma.
  • [MeSH-major] Head and Neck Neoplasms

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20093222.001).
  • [ISSN] 1993-0836
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mali
  •  go-up   go-down


62. Pianta A, Puppin C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, Filetti S, Russo D, Damante G: Nucleophosmin is overexpressed in thyroid tumors. Biochem Biophys Res Commun; 2010 Jul 2;397(3):499-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleophosmin is overexpressed in thyroid tumors.
  • Depending on the context, it can act as an oncogene or tumor suppressor.
  • No data are available on NPM expression in thyroid cells.
  • In this work, we analyzed both NPM mRNA and protein levels in a series of human thyroid tumor tissues and cell lines.
  • By using immunohistochemistry, NPM overexpression was detected in papillary, follicular, undifferentiated thyroid cancer, and also in follicular benign adenomas, indicating it as an early event during thyroid tumorigenesis.
  • In contrast, various levels of NPM mRNA levels as detected by quantitative RT-PCR were observed in tumor tissues, suggesting a dissociation between protein and transcript expression.
  • The same behavior was observed in the normal thyroid FRTL5 cell lines.
  • By using thyroid tumor cell lines, we demonstrated that such a post-mRNA regulation may depend on NPM binding to p-Akt, whose levels were found to be increased in the tumor cells, in parallel with reduction of PTEN.
  • In conclusion, our present data demonstrate for the first time that nucleophosmin is overexpressed in thyroid tumors, as an early event of thyroid tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cell Transformation, Neoplastic / metabolism. Nuclear Proteins / biosynthesis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Humans. Proto-Oncogene Proteins c-akt / metabolism. Thyroid Gland / metabolism. Transcription, Genetic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20515654.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


63. Türköz HK, Oksüz H, Yurdakul Z, Ozcan D: Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol; 2008;19(2):92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma.
  • Galectin-3 expression has been evaluated in various malignant neoplasms to determine its effectiveness in differential diagnosis from benign lesions and its effects on carcinogenesis.
  • There are few and somewhat controversial results regarding its changes through cancer progression in thyroid malignancies.
  • We studied the presence of galectin-3 expression immunohistochemically and its relation with tumor invasiveness and lymph node metastasis in 89 cases of papillary carcinoma of the thyroid.
  • Galectin-3 overexpression is more profound in early stages of papillary carcinoma, and its expression intensity decreases during tumor progression.
  • This finding is consistent with roles for galectin-3 in cell adhesion to other tumor cells and the matrix.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Galectin 3 / biosynthesis. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aging / pathology. Biomarkers, Tumor. Disease Progression. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Metastasis / pathology. Paraffin Embedding. Retrospective Studies. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 1998 Jun;12(6):1287-90 [9592187.001]
  • [Cites] J Pathol. 1996 May;179(1):43-8 [8691344.001]
  • [Cites] Cell Mol Biol Lett. 2004;9(2):305-28 [15213811.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):449-53 [14585093.001]
  • [Cites] Head Neck. 2005 Dec;27(12):1049-55 [16155918.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):428-33 [10821488.001]
  • [Cites] Int J Oncol. 1999 Jul;15(1):143-8 [10375607.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):787-92 [11251175.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1069-75 [11891203.001]
  • [Cites] Am J Clin Pathol. 2006 Mar;125(3):399-406 [16613343.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Aug;25(4):319-30 [10476049.001]
  • [Cites] Histopathology. 2006 Jun;48(7):795-800 [16722927.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):48-57 [15272279.001]
  • [Cites] Exp Cell Res. 1998 Dec 15;245(2):294-302 [9851870.001]
  • [Cites] Acta Cytol. 2006 Sep-Oct;50(5):518-28 [17017437.001]
  • [Cites] J Natl Cancer Inst. 1992 Aug 5;84(15):1161-9 [1386115.001]
  • [Cites] Biochem Soc Trans. 1992 May;20(2):269-74 [1397610.001]
  • [Cites] Int J Cancer. 2000 Feb 15;85(4):545-54 [10699929.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6):1906-15 [9394730.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4530-4 [8813152.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3015-20 [9679965.001]
  • (PMID = 18581271.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3
  •  go-up   go-down


64. Besic N, Sesek M, Peric B, Zgajnar J, Hocevar M: Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit; 2008 Sep;14(9):CR459-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid.
  • BACKGROUND: The aim of this retrospective study was to find predictive factors of carcinoma in patients with follicular neoplasm.
  • The specific aim was to discover whether preoperative serum thyroglobulin (Tg) concentration in patients with thyroid neoplasm can differentiate between those with thyroid carcinoma and those with benign disease.
  • MATERIAL/METHODS: A total of 327 patients (263 females, 64 males, median age: 51.5 years) with follicular neoplasm in whom carcinoma was only suspected and who were surgically treated at the authors' institute in 1988-2004 were included in the study.
  • RESULTS: The histopathological diagnoses were carcinoma, benign goiter, and adenoma in 119 (36%), 104 (32%), and 104 (32%) patients, respectively.
  • The independent predictors of malignancy as shown by multivariate logistic regression were tumor diameter and preoperative Tg concentration.
  • Thyroid carcinoma was more common in the patients with follicular neoplasm and serum Tg concentration over 300 ng/ml than in those with lower Tg concentrations.
  • CONCLUSIONS: Predictors of malignancy were tumor diameter and preoperative Tg concentration.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / diagnosis. Thyroid Neoplasms / blood. Thyroid Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758416.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


65. Ezon I, Zilbert N, Pinkney L, Wei JJ, Malik R, Nadler EP: A large struma ovarii tumor removed via laparoscopy in a 16-year-old adolescent. J Pediatr Surg; 2007 Aug;42(8):E19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A large struma ovarii tumor removed via laparoscopy in a 16-year-old adolescent.
  • Struma ovarii is rare ovarian tumor that is characterized by the presence of at least 50% thyroid tissue on histologic examination.
  • This usually benign neoplasm is predominantly found in women between the ages of 40 and 60 years and infrequently in the pediatric age group.
  • We conclude that the diagnosis of struma ovarii should be considered in adolescent girls presenting with large cystic ovarian masses and that a laparoscopic approach to management is the treatment of choice.
  • [MeSH-major] Laparoscopy. Ovarian Neoplasms / surgery. Ovariectomy / methods. Struma Ovarii / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706482.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Sancak S, Hardt A, Gärtner R, Eszlinger M, Aslan A, Eren FT, Güllüoglu BM, Sen LS, Sever Z, Akalin NS, Paschke R: Comparison of Color Flow Doppler Sonography (CFDS) and immunohistologic detection of microvessels for the assessment of the malignancy of thyroid nodules. Horm Metab Res; 2010 Aug;42(9):670-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Color Flow Doppler Sonography (CFDS) and immunohistologic detection of microvessels for the assessment of the malignancy of thyroid nodules.
  • The assessment of tumor vascularization by color flow Doppler sonography (CFDS) has been suggested for the distinction between benign and malignant thyroid nodules.
  • Tissue sections from 10 adenomas, 8 ANs and 13 PC and surrounding tissue of 10 PCs and 2 benign nodules were immunostained for CD34.
  • A ROC analysis on the basis of the histologically determined number of microvessels demonstrated 70% microvessels as an optimal cut point for the diagnosis of PC with the highest sensitivity of 92% and highest specificity of 89%.
  • [MeSH-major] Microvessels / pathology. Microvessels / ultrasonography. Thyroid Nodule / blood supply. Thyroid Nodule / ultrasonography. Ultrasonography, Doppler, Color

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20568034.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


67. Letsas KP, Frangou-Lazaridis M, Skyrlas A, Tsatsoulis A, Malamou-Mitsi V: Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions. Pathol Int; 2005 Nov;55(11):694-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.
  • Proliferation and apoptosis-related transcription factor immunoexpression patterns were concomitantly investigated in tissue sections of normal thyroid, goiters, follicular adenomas and well-differentiated papillary and follicular carcinomas using antibodies against prothymosin alpha, E2F-1, p53, Bcl2, and Bax proteins.
  • Positive Bcl2 immunostaining was detected in all thyroid histotypes.
  • These data demonstrate that prothymosin alpha and E2F-1 are strongly involved in the proliferation processes of thyroid neoplasias.
  • [MeSH-major] Apoptosis. Cell Proliferation. Thyroid Diseases / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology. Transcription Factors / physiology
  • [MeSH-minor] Adenoma / pathology. Adenoma / physiopathology. Adolescent. Adult. Aged. Carcinoma, Papillary, Follicular / pathology. Carcinoma, Papillary, Follicular / physiopathology. DNA-Binding Proteins / analysis. DNA-Binding Proteins / immunology. DNA-Binding Proteins / physiology. E2F1 Transcription Factor / analysis. E2F1 Transcription Factor / immunology. E2F1 Transcription Factor / physiology. Female. Goiter / pathology. Goiter / physiopathology. Humans. Immunohistochemistry. Male. Middle Aged. Protein Precursors / analysis. Protein Precursors / immunology. Protein Precursors / physiology. Repressor Proteins / analysis. Repressor Proteins / immunology. Repressor Proteins / physiology. Thymosin / analogs & derivatives. Thymosin / analysis. Thymosin / immunology. Thymosin / physiology. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / immunology. Tumor Suppressor Protein p53 / physiology. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / immunology. Tumor Suppressor Proteins / physiology. bcl-2-Associated X Protein / analysis. bcl-2-Associated X Protein / immunology. bcl-2-Associated X Protein / physiology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271081.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BCLAF1 protein, human; 0 / DNA-Binding Proteins; 0 / E2F1 Transcription Factor; 0 / Protein Precursors; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 0 / prothymosin alpha; 61512-21-8 / Thymosin
  •  go-up   go-down


68. Mathur A, Weng J, Moses W, Steinberg SM, Rahbari R, Kitano M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E: A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery; 2010 Dec;148(6):1170-6; discussion 1176-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy.
  • BACKGROUND: Approximately 30% of fine needle aspiration biopsies of the thyroid have inconclusive results.
  • We conducted a prospective trial to determine whether clinical and molecular markers could be used in combination to improve the accuracy of thyroid fine needle aspiration biopsy.
  • METHODS: Clinical, tumor genotyping for common somatic mutations (BRAF V600E, NRAS, KRAS, RET/PTC1, RET/PTC3, and NTRK1), and the gene expression levels of 6 candidate diagnostic markers were analyzed by univariate and multivariate methods in 341 patients to determine whether they could distinguish reliably benign from malignant thyroid neoplasms, and a scoring model was derived.
  • The overall accuracy of the scoring model, including these 3 variables, to distinguish benign from malignant thyroid tumors was 91%, including 67% for the indeterminate and 77% for the suspicious FNA subgroups.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Thyroid Diseases / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Ethnic Groups. Female. Genes, ras / genetics. Humans. Male. Medical History Taking. Middle Aged. Multivariate Analysis. Mutation. Prospective Studies. RNA / genetics. RNA / isolation & purification. RNA, Neoplasm / genetics. RNA, Neoplasm / isolation & purification. Reproducibility of Results. Thyroidectomy / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Mosby, Inc.
  • [Cites] Cancer. 2000 Dec 25;90(6):357-63 [11156519.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):477-82 [11601131.001]
  • [Cites] Arch Surg. 2002 Jul;137(7):818-21 [12093339.001]
  • [Cites] Endocr Pract. 2003 Mar-Apr;9(2):128-36 [12917075.001]
  • [Cites] Ann Intern Med. 1968 Sep;69(3):537-40 [5673172.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2592-7 [16688775.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Curr Opin Oncol. 2008 Jan;20(1):13-8 [18043251.001]
  • [Cites] Cancer. 2009 Mar 1;115(5):972-80 [19152441.001]
  • [Cites] CA Cancer J Clin. 2009 Mar-Apr;59(2):99-110 [19278960.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):2977-82 [19414674.001]
  • [Cites] Diagn Cytopathol. 2009 Oct;37(10):710-4 [19373907.001]
  • [Cites] Surg Clin North Am. 2009 Oct;89(5):1139-55 [19836489.001]
  • [Cites] Surgery. 2009 Dec;146(6):1215-23 [19958951.001]
  • [Cites] Curr Opin Oncol. 2010 Jan;22(1):23-9 [19907326.001]
  • [Cites] Thyroid. 2009 Dec;19(12):1351-61 [19895341.001]
  • [Cites] Mol Cell Endocrinol. 2010 May 28;321(1):77-85 [19932149.001]
  • [Cites] J Surg Res. 2010 May 15;160(2):179-83 [19765726.001]
  • [Cites] Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28 [20138116.001]
  • [ErratumIn] Surgery. 2012 Feb;151(2):343. Rahabari, Reza [corrected to Rahbari, Reza]
  • (PMID = 21134548.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 63231-63-0 / RNA
  • [Other-IDs] NLM/ NIHMS240002; NLM/ PMC3052943
  •  go-up   go-down


69. Ferreira RC, Ward LS, Adam RL, Leite NJ, Metze K, Matos PS: [Contribution of nuclear texture analysis for the differential diagnosis of follicular lesions of the thyroid: comparison to immunohistochemical markers]. Arq Bras Endocrinol Metabol; 2009 Oct;53(7):804-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of nuclear texture analysis for the differential diagnosis of follicular lesions of the thyroid: comparison to immunohistochemical markers].
  • [Transliterated title] Contribuição da análise de textura do núcleo celular para o diagnóstico diferencial de lesões foliculares da tireoide: comparação com marcadores imunoistoquímicos.
  • OBJECTIVE AND METHODS: To investigate the utility of nuclear chromatin texture assessment in the differential diagnosis of follicular patterned lesions, by means of examining 76 samples previously submitted to the immunohistochemical protein analysis of HBME-1, CK-19 and galectina-3.
  • Among these variables, r(2), a parameter related to the granularity of the nucleus presented the best accuracy, sensitivity, specificity and positive and negative predictive values, distinguishing benign from malignant lesions.
  • CONCLUSION: The morphometric analysis of nuclear chromatin images may add accuracy to the differential diagnosis of follicular patterned lesions.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Papillary, Follicular / pathology. Cell Nucleus / pathology. Chromatin / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Computer-Assisted / methods. Diagnosis, Differential. Galectin 3 / analysis. Humans. Keratin-19 / analysis. Predictive Value of Tests. Software

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arq Bras Endocrinol Metabol. 2009 Oct;53(7):793-4 [19942979.001]
  • (PMID = 19942981.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromatin; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19
  •  go-up   go-down


70. Sousa MS, Latini FR, Monteiro HP, Cerutti JM: Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors. Free Radic Biol Med; 2010 Sep 15;49(6):997-1007
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors.
  • We have previously shown that ARG2 expression was increased in most malignant thyroid tumors, but absent in benign lesions and normal tissues.
  • Small interfering RNA knockdown was used to investigate the role of ARG2 in a thyroid carcinoma cell line.
  • ARG2 silencing changed tumor properties of thyroid cancer cells promoting apoptosis and reduced expression of cell proliferation markers.
  • Additionally, a positive correlation of ARG2 with eNOS and related genes was investigated in thyroid tumors, further substantiating our in vitro findings.
  • Our results suggest that ARG2 and eNOS may work in a coordinated manner and the underlying mechanism might be of major significance for thyroid tumorigenesis and/or tumor progression pathways.
  • [MeSH-major] Arginase / metabolism. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Nitric Oxide Synthase / metabolism. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Apoptosis / genetics. Cell Line, Tumor. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Progression. Gene Expression Regulation, Neoplastic / genetics. Humans. Oxidative Stress / genetics. RNA, Small Interfering / genetics. Signal Transduction / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20542107.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Small Interfering; EC 1.14.13.39 / Nitric Oxide Synthase; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


71. Kim DH, Murovic JA, Tiel RL, Moes G, Kline DG: A series of 146 peripheral non-neural sheath nerve tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg; 2005 Feb;102(2):256-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: This is a retrospective review of 146 surgically treated benign and malignant peripheral non-neural sheath tumors (PNNSTs).
  • Tumor classifications with patient numbers, locations of benign PNNSTs, and surgical techniques and adjunctive treatments are presented.
  • The results of a literature review regarding tumor frequencies are presented.
  • METHODS: One hundred forty-six patients with 111 benign and 35 malignant PNNSTs were treated between 1969 and 1999 at the Louisiana State University Health Sciences Center (LSUHSC).
  • The benign tumors included 33 ganglion cysts, 16 cases of localized hypertrophic neuropathy, 12 lipomas, 12 tumors of vascular origin, and 11 desmoid tumors.
  • The locations of benign PNNSTs were the following: 33 in the brachial plexus region, 39 in an upper extremity, one in the pelvic plexus, and 38 in a lower extremity.
  • There were two melanomas metastatic to nerve and one tumor each that had metastasized from the bladder, rectum, skin, head and neck, and thyroid, and from a primary Ewing sarcoma.
  • CONCLUSIONS: There were more benign PNNSTs than malignant ones.
  • Benign tumors were relatively equally distributed in the brachial plexus region and upper and lower extremities, with the exception of the pelvic plexus, which had only one tumor.
  • [MeSH-major] Brachial Plexus Neuropathies / surgery. Hypogastric Plexus / surgery. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Academic Medical Centers. Arm / innervation. Brachial Plexus / pathology. Brachial Plexus / surgery. Diagnosis, Differential. Electromyography. Follow-Up Studies. Humans. Leg / innervation. Louisiana. Magnetic Resonance Imaging. Neurologic Examination. Peripheral Nerves / pathology. Peripheral Nerves / surgery. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739553.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Zhao Z, Wei Q, Zhao Y, Sun F, Jin X, Cui B, Ning G: Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules. Endocrine; 2009 Aug;36(1):155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules.
  • Thyroid nodules were the extremely common endocrine tumors, in which papillary thyroid carcinomas (PTCs) were the most prevalent endocrine malignancy, representing 80-90% of all thyroid malignancies.
  • It was still a dilemma to discriminate PTCs and benign thyroid nodules.
  • With a new molecular genetics technology of Multiplex ligation-dependent probe amplification (MLPA), we investigated 13 PTC and 14 benign nodule tissue samples.
  • The results showed that PTCs had more genetic copy number alteration than benign nodules (P < 0.001).
  • Receiver operating characteristic (ROC) curve analysis suggested that genomic aberrations would provide a moderate accuracy method to discriminate PTCs and benign nodules.
  • The gain of interleukin 13 (IL-13) gene obviously identified the great difference between PTCs and benign nodules.
  • The current study showed that MLPA should be an effective method to diagnose PTCs and benign thyroid nodules, and also provided a clue to another relationship between IL-13 and PTCs.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Papillary / genetics. Interleukin-13 / genetics. Neoplasms / genetics. Thyroid Neoplasms / genetics. Thyroid Nodule / genetics
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Gene Dosage. Genetic Testing / methods. Humans. Immunohistochemistry. Male. Middle Aged. Thyroid Gland / metabolism. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1995 Dec 21;11(12):2459-67 [8545102.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1631-42 [16884377.001]
  • [Cites] Oncogene. 2008 Jul 31;27(33):4592-602 [18408749.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3735-9 [8097324.001]
  • [Cites] J Dermatol Sci. 2005 Oct;40(1):51-7 [16054806.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):948-53 [9258124.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3583-8 [8758930.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2035-43 [15041723.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):625-37 [9683604.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1743-9 [9816125.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):666-9 [9024273.001]
  • [Cites] Dig Liver Dis. 2008 Apr;40(4):240-7 [18243827.001]
  • [Cites] Br J Cancer. 2000 May;82(10):1717-23 [10817509.001]
  • [Cites] Nature. 1993 Mar 18;362(6417):248-50 [8096327.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17 ):1764-71 [15496625.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] Int J Colorectal Dis. 2009 Jan;24(1):57-67 [18758789.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):9-16 [15714058.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17193-201 [10358077.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2414-20 [15126572.001]
  • [Cites] Blood. 1994 Sep 15;84(6):1913-21 [7521694.001]
  • [Cites] Surgery. 2000 Dec;128(6):888-93;discussion 893-4 [11114620.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1539-47 [10329606.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):296-301 [15483090.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):65-73 [17227125.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • (PMID = 19507063.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-13
  •  go-up   go-down


73. Mete O, Rotstein L, Asa SL: Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol; 2010 Feb;17(2):386-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension.
  • INTRODUCTION AND DESIGN: Endocrine pathologists, surgeons, and oncologists who manage patients with thyroid carcinomas confront many critical dilemmas.
  • Controversies surrounding diagnostic criteria that distinguish benign from malignant thyroid follicular lesions have been brought to the attention of this community.
  • In this article, we confront another controversy, the definition of a thyroid "capsule" to clarify what constitutes extrathyroidal extension (ETE) and its clinical significance in the management of patients with differentiated thyroid carcinomas.
  • RESULTS AND CONCLUSION: Our review of the anatomy of the thyroid gland confirms that this structure has no defined anatomical fibrous capsule.
  • Moreover, the presence of adipose tissue within the thyroid gland and its pseudocapsule implies that thyroid tumor within fat tissue cannot be accepted as a criterion of ETE by that thyroid carcinoma.
  • While invasion of skeletal muscle is a more reliable feature of ETE, at the isthmus, these fibers can be normally present within the gland, and this criterion does not have value.
  • [MeSH-major] Connective Tissue / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Thyroid Gland / anatomy & histology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949881.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


74. Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, Fadda G: Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer; 2005 Apr 25;105(2):87-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies.
  • BACKGROUND: Fine-needle aspiration biopsy (FNAB) is the most reliable diagnostic tool for thyroid nodules.
  • A difficult cytologic diagnosis may be supported by an immunocytochemical study.
  • DESIGN: Thyroid FNABs (n = 99) with both conventional (CS) and thin-layer cytology (TLC) smears were studied.
  • The cases were diagnosed as follows: 5 benign lesions (BL), 13 papillary carcinomas (PC), and 81 follicular proliferations (FP).
  • The category of FP was divided into three subgroups according to nuclear features of follicular cells: Follicular neoplasm (FN NOS), oxyphilic follicular neoplasm (OFN), and follicular lesion with nuclear pleomorphism (FLWNP).
  • Out of 37 FP, the ICCP yielded positive in 15 cases (4 benign, 11 malignant) and negative in 11 (all benign).
  • In the FLWNP subgroup, the ICCP was positive in 11 (84.6%) and negative in 2 histologically benign cases.
  • CONCLUSION: The combined panel of antibodies and the nuclear pleomorphism of follicular cells were effective in distinguishing between thyroid nodules requiring surgery from thyroid nodules requiring just follow-up.
  • [MeSH-major] Cytodiagnosis / methods. Immunohistochemistry / methods. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies. Biomarkers, Tumor / immunology. Biopsy, Fine-Needle. Carcinoma, Papillary / pathology. Female. Galectin 3 / immunology. Humans. Male. Middle Aged. Oncogene Proteins / immunology. Proto-Oncogene Proteins c-ret. Receptor Protein-Tyrosine Kinases / immunology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 American Cancer Society.
  • (PMID = 15742329.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Oncogene Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


75. Asaad NY, Abd El-Wahed MM, Mohammed AG: Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma: diagnostic and prognostic role. J Egypt Natl Canc Inst; 2006 Mar;18(1):8-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma: diagnostic and prognostic role.
  • AIM OF WORK: Therefore we thought to determine whether hTERT gene detection could serve as an adjunct in the diagnosis of thyroid lesions together with evaluation of its prognostic value.
  • PATIENTS AND METHODS: The study included 50 cases of primary thyroid carcinoma including; 28 papillary carcinoma, 14 follicular carcinoma, 5 anaplastic carcinoma and 3 medullary carcinoma in addition to 5 cases of nodular hyperplasia and 5 cases of follicular adenoma.
  • RESULTS: RT-PCR of hTERT gene revealed expression in 43/50 (86%) malignant thyroid cases; including 25 papillary, 11 follicular, 4 anaplastic and 3 medullary carcinoma cases.
  • The diagnostic validity of hTERT gene detection in benign and malignant thyroid lesions was in the form of 88.3% accuracy, 86% sensitivity, 100% specificity, 100% positive predictive value and 90% negative predictive value.
  • In thyroid carcinoma cases, hTERT gene detection was the most independent predictor of poor survival by multivariate survival analysis.
  • CONCLUSION: Detection of hTERT gene expression should be considered in confirmation of malignant thyroid lesions.
  • Moreover it could be one of the helpful tools in addition to grade, tumor type, and age to stratify patients with thyroid carcinoma into different prognostic categories.
  • Hence, inhibition of hTERT could be of use prospectively in the era of cancer therapy as an attractive weapon in thyroid carcinoma.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / enzymology. Telomerase / biosynthesis. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / enzymology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Gene Expression. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237847.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


76. Minato H, Nojima T, Kurose N, Kinoshita E: Adenomatoid tumor of the pleura. Pathol Int; 2009 Aug;59(8):567-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the pleura.
  • A case of adenomatoid tumor of the pleura is reported, and its differential diagnosis from benign and malignant pleural lesions is discussed.
  • A 7 mm, circumscribed tumor had characteristic features of adenomatoid tumor.
  • The tumor was composed of an aggregation of irregularly shaped tubulocystic spaces with fibrous stoma.
  • On immunohistochemistry the tumor cells were positive for AE1/AE3, CAM5.2, vimentin, cytokeratin 5/6, D2-40, calretinin, thrombomodulin, and WT-1, but negative for CEA, Leu M1 (CD15), thyroid transcription factor-1, epithelial membrane antigen, desmin, glucose transporter-1 (GLUT-1), CD31, and CD34.
  • Adenomatoid tumor of the pleura is rare, and the pathogenesis has not been elucidated.
  • Recognition of these benign mesothelial lesions in the pleura is important to avoid misdiagnosis.
  • [MeSH-major] Adenomatoid Tumor / pathology. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Dermatomyositis / complications. Esophageal Neoplasms / complications. Esophageal Neoplasms / pathology. Female. Humans. Immunohistochemistry. Incidental Findings. Liver Cirrhosis, Biliary / complications. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627540.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Boi F, Maurelli I, Pinna G, Atzeni F, Piga M, Lai ML, Mariotti S: Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab; 2007 Jun;92(6):2115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma.
  • OBJECTIVE: The aim of the study was to evaluate the usefulness of calcitonin (CT) assay in fine-needle aspiration biopsy (FNAB) wash-out fluid alone or combined with cytology in the presurgical study of medullary thyroid carcinoma (MTC) patients with thyroid nodules (TNs) and of suspicious neck MTC recurrences/metastases.
  • Of the 15 negative CT-FNAB suspicious masses (eight TNs, six LNs, and one LR), five displayed a benign lesion at histology.
  • The remaining 10 cases, all with benign cytology, were not operated on, and no evidence of MTC was detected at follow-up.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Calcitonin / metabolism. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Body Fluids / metabolism. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Thyroid Nodule / metabolism. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405835.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


78. Dionigi G, Dionigi R, Bartalena L, Tanda ML, Piantanida E, Castano P, Annoni M, Boni L, Rovera F, Bacuzzi A, Vanoli P, Sessa F: [Current indications for thyroidectomy]. Minerva Chir; 2007 Oct;62(5):359-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid surgery, one of the most common interventions in endocrine surgery, is practiced by many specialists who perform this procedure exclusively.
  • Surgeons who correctly perform thyroid surgery can achieve excellent outcomes even in other areas of endocrine surgery.
  • Numerous studies have reported that the incidence of complications is high and that the rate is growing: 5% involve permanent injury to the recurrent laryngeal nerve after intervention for a benign tumor, despite repeated reports that the incidence could be reduced to near zero or at least to 1%.
  • [MeSH-major] Thyroid Diseases / surgery. Thyroidectomy
  • [MeSH-minor] Algorithms. Ambulatory Surgical Procedures. Goiter, Nodular / surgery. Graves Disease / surgery. Humans. Minimally Invasive Surgical Procedures. Thyroid Neoplasms / surgery. Thyroid Nodule / surgery. Thyrotoxicosis / surgery. Treatment Outcome. Video-Assisted Surgery

  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947947.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 105
  •  go-up   go-down


79. Wynveen C, Behmaram B, Haasler G, Rao N: Diverse histologic appearances in pulmonary mucinous cystic neoplasia: a case report. J Med Case Rep; 2008;2:312
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diverse histologic appearances in pulmonary mucinous cystic neoplasia: a case report.
  • INTRODUCTION: Primary pulmonary mucinous cystic neoplasia comprises a group of tumors, from benign cystadenoma to mucinous cystadenocarcinoma.
  • A lobectomy was performed and the resection specimen revealed a multicystic mucinous tumor.
  • Microscopically, the tumor was composed of confluent mucin-filled cystic spaces lined by columnar mucin-secreting cells which ranged from cytologically bland to moderately atypical with 'bronchioloalveolar pattern' invasion into the adjacent parenchyma.
  • Immunohistochemically, tumor cells were positive diffusely for Cytokeratin 7, and focally for Cytokeratin 20 and Thyroid Transcription Factor-1.
  • CONCLUSION: This case highlights the continuous spectrum of pulmonary mucinous cystic neoplasia from benign mucinous cystadenoma to malignant mucinous cystadenocarcinoma, and the probable existence of a 'borderline' mucinous cystic tumor.
  • Although molecular data are lacking to substantiate progression from benign to malignant in these neoplasms, the importance of recognizing the morphologic continuum lies in alerting pathologists to thoroughly examine specimens to rule out invasive foci in tumors with 'borderline' morphology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2005 Jul;28(1):176-7 [15939602.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):62-70 [15923171.001]
  • [Cites] Cancer. 1995 Nov 1;76(9):1540-4 [8635055.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):722-8 [8317612.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):958-62 [16831050.001]
  • [Cites] Hum Pathol. 1991 Feb;22(2):185-90 [2001880.001]
  • [Cites] Mod Pathol. 1992 Nov;5(6):634-8 [1369799.001]
  • [Cites] Thorax. 1978 Dec;33(6):796-9 [746508.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):442-52 [15087663.001]
  • [Cites] Ann Thorac Surg. 2003 Nov;76(5):1738-40 [14602331.001]
  • [Cites] J Clin Pathol. 2002 Feb;55(2):156 [11865017.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):696-7 [11235730.001]
  • (PMID = 18823534.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2564958
  •  go-up   go-down


80. Shantaram M, Rao A, Aroor AR, Raja A, Rao S, Monteiro F: Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann Indian Acad Neurol; 2009 Jul;12(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression.
  • The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors.
  • OBJECTIVE: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients.
  • The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients.
  • DISCUSSION: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors.
  • TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1992;24(2):125-9 [1624255.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):91-100 [2049789.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Aug;49(8):843-7 [2072195.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):139-42 [2298100.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):17-20 [2663215.001]
  • [Cites] Thyroid. 2005 Jul;15(7):645-52 [16053379.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):912-7 [10841826.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1815-9 [7116306.001]
  • [Cites] Clin Biochem. 1980 Oct;13(5):191-7 [7006855.001]
  • [Cites] Anticancer Res. 1984 Jul-Oct;4(4-5):313-6 [6486735.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1389-94 [3948121.001]
  • [Cites] Int J Biol Markers. 1988 Oct-Dec;3(4):243-8 [3235852.001]
  • [Cites] Clin Chim Acta. 1988 Sep 15;176(3):251-7 [3180477.001]
  • [Cites] Neurol Res. 1986 Jun;8(2):123-6 [2875407.001]
  • [Cites] Obstet Gynecol. 1988 Jan;71(1):20-6 [2827081.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • (PMID = 20174496.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824932
  • [Keywords] NOTNLM ; Brain tumors / lipid-bound sialic acid / total sialic acid / tumor markers
  •  go-up   go-down


81. Muñoz E, Prat A, Adamo B, Peralta S, Ramón y Cajal S, Valverde C: A rare case of malignant solitary fibrous tumor of the spinal cord. Spine (Phila Pa 1976); 2008 May 20;33(12):E397-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of malignant solitary fibrous tumor of the spinal cord.
  • OBJECTIVE: We present a case of an ambulatory patient with a solitary fibrous tumor of the spinal cord.
  • SUMMARY OF BACKGROUND DATA: Solitary fibrous tumor (SFT) is an uncommon mesenchymal tumor of the pleural cavity, increasingly recognized at numerous extrathoracic sites, including, among others, prostate, kidney, and thyroid.
  • Although SFTs are usually indolent neoplasms that are cured with complete surgical resection, malignant transformation has been described within histologically benign SFTs.
  • RESULTS: We report the first case of spinal cord SFT with visceral dissemination years after the primary diagnosis, despite benign histologic features of the primary tumor.
  • [MeSH-major] Liver Neoplasms / secondary. Lung Neoplasms / secondary. Solitary Fibrous Tumors / pathology. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496336.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vimentin
  • [Number-of-references] 14
  •  go-up   go-down


82. Sassolas G, Hafdi-Nejjari Z, Schott AM, Bournaud C, Peix JL, Orgiazzi J, Dutrieux-Berger N, Borson-Chazot F, Group of Pathologists of the Rhône-Alpes Région: Geographical correlation between incidence of benign disease and that of cancer of the thyroid among the population of the Rhône-Alpes Région of France. Eur J Endocrinol; 2010 Jan;162(1):127-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographical correlation between incidence of benign disease and that of cancer of the thyroid among the population of the Rhône-Alpes Région of France.
  • OBJECTIVE: To analyze, at a population level, the relation between the incidences of benign thyroid diseases in patients submitted to surgery and that of thyroid cancers based on their respective geographical distributions.
  • METHODS: The study included 3169 cases (691 cancers and 2478 benign diseases) operated on in 2002 in the Rhône-Alpes région, which is subdivided into eight départements and 311 cantons.
  • RESULTS: The total thyroid intervention rate was 54.6/100 000 (23.4 and 86.4), and the annual cancer incidence was 11.9/100 000 (4.7 and 13.8) for men and women respectively.
  • The prevalence of cancer among thyroid surgery was 21.8% and that of cancer discovered in goiters increased with age (44% at 60 years).
  • In women, the incidence of microcancers was correlated to the thyroid intervention for benign pathologies rate.
  • At the canton level, the relative risk of benign diseases was correlated to that of cancers.
  • CONCLUSION: In the Rhône-Alpes population with high rates of thyroid cancer incidence and of thyroid surgery, a number of correlations were found according to gender and tumor size.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19797258.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Bomeli SR, LeBeau SO, Ferris RL: Evaluation of a thyroid nodule. Otolaryngol Clin North Am; 2010 Apr;43(2):229-38, vii
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a thyroid nodule.
  • The thyroid specialist frequently evaluates thyroid nodules because they may represent malignancy.
  • Yet, the majority of thyroid nodules are asymptomatic and benign, so the thyroid surgeon must rely on diagnostic studies to determine when surgery is indicated.
  • Ultrasound is the preferred imaging modality for thyroid nodules, and the ultrasound guided fine-needle aspiration biopsy (FNAB) is the preferred method of tissue sampling.
  • Detecting malignancy preoperatively allows total thyroidectomy in a single operation without the need for frozen section or a second operation for completion of a thyroidectomy if malignancy is found during the initial thyroid lobectomy.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):775-9 [11448348.001]
  • [Cites] Endocr Pract. 2001 Jul-Aug;7(4):237-43 [11497473.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1941-6 [11994321.001]
  • [Cites] ANZ J Surg. 2002 Aug;72(8):570-2 [12190731.001]
  • [Cites] Am J Surg. 2002 Dec;184(6):510-4; discussion 514 [12488150.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1870-84 [14603040.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jan;60(1):21-8 [14678283.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):163-8 [14715844.001]
  • [Cites] Radiology. 2004 May;231(2):305-32 [15044750.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 [15472223.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1764-71 [15496625.001]
  • [Cites] Thyroid. 2007 Jun;17(6):557-65 [17614777.001]
  • [Cites] Arch Intern Med. 1994 Aug 22;154(16):1838-40 [8053752.001]
  • [Cites] Immunol Today. 1995 Oct;16(10):487-94 [7576053.001]
  • [Cites] Surgery. 1995 Dec;118(6):996-1003; discussion 1003-4 [7491545.001]
  • [Cites] Otolaryngol Clin North Am. 1996 Aug;29(4):577-91 [8844731.001]
  • [Cites] Cancer. 1997 Aug 25;81(4):253-9 [9292740.001]
  • [Cites] Thyroid. 1998 Jan;8(1):15-21 [9492148.001]
  • [Cites] Thyroid. 1998 May;8(5):393-8 [9623729.001]
  • [Cites] J Clin Endocrinol Metab. 1955 Oct;15(10):1270-80 [13263417.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 [16174717.001]
  • [Cites] Surgery. 2005 Dec;138(6):1166-74; discussion 1174-5 [16360405.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):216-22 [16434896.001]
  • [Cites] J Nucl Med. 2006 May;47(5):770-5 [16644746.001]
  • [Cites] Thyroid. 2006 Feb;16(2):109-42 [16420177.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):61-5 [16760581.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7 [16835280.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Nov;65(5):660-6 [17054470.001]
  • [Cites] Nucl Med Commun. 2007 May;28(5):373-81 [17414887.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Jul;139(1):21-6 [18585556.001]
  • [Cites] Endocrinol Metab Clin North Am. 2008 Jun;37(2):401-17, ix [18502334.001]
  • [Cites] Diagn Cytopathol. 2008 Jun;36(6):425-37 [18478609.001]
  • [Cites] Clin Otolaryngol. 2008 Feb;33(1):63-6 [18302559.001]
  • [Cites] Surgery. 2007 Dec;142(6):837-44; discussion 844.e1-3 [18063065.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):678-83 [17381488.001]
  • [Cites] Endocrinol Metab Clin North Am. 2001 Jun;30(2):339-60, viii-ix [11444166.001]
  • [Cites] World J Surg. 2000 Aug;24(8):934-41 [10865037.001]
  • [Cites] Semin Nucl Med. 2000 Apr;30(2):81-7 [10787188.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8 [19318445.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 May;17(3):211-5 [19384080.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9 [18682506.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • (PMID = 20510711.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115902-04; United States / NCI NIH HHS / CA / R01 CA115902; United States / NCI NIH HHS / CA / R01 CA115902-04
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 44
  • [Other-IDs] NLM/ NIHMS177041; NLM/ PMC2879398
  •  go-up   go-down


84. Chia SY, Milas M, Reddy SK, Siperstein A, Skugor M, Brainard J, Gupta MK: Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. J Clin Endocrinol Metab; 2007 Feb;92(2):468-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer.
  • CONTEXT: Thyroid cancer cells express TSH receptor (TSHR) mRNA, and its measurement in the circulation may be useful in the diagnosis/management of differentiated thyroid cancer (DTC).
  • OBJECTIVE: Our objective was to assess the diagnostic value of circulating TSHR mRNA for preoperative detection of DTC in patients with thyroid nodules.
  • PATIENTS: We measured TSHR mRNA levels by RT-PCR in 258 subjects: 51 healthy subjects and 207 patients (thyroid nodules, n = 180; recurrent thyroid cancer, n = 27) with fine-needle aspirations (FNA) and/or thyroid/neck surgery.
  • RESULTS: Based on cytology/pathology, 88 patients had DTC and 119 had benign thyroid disease.
  • The TSHR mRNA levels in cancer patients were significantly higher than in benign disease (P < 0.0001).
  • Of 131 patients with FNA and surgery, 51 were FNA positive (all cancer), 17 were FNA negative (15 benign, two cancer), and 63 were indeterminate.
  • TSHR mRNA correctly diagnosed DTC in 16 of 24 (67%) and benign disease in 29 of 39 (74%) patients with indeterminate FNA (combined sensitivity = 90%; specificity = 80%).
  • Combining TSHR mRNA and ultrasound features for follicular lesions correctly classified all follicular cancers and could have spared surgery in 31% of these patients with benign disease.
  • CONCLUSIONS: TSHR mRNA measured with FNA enhances the preoperative detection of cancer in patients with thyroid nodules, reducing unnecessary surgeries, and immediate postoperative levels can predict residual/metastatic disease.
  • [MeSH-major] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / blood. Neoplastic Cells, Circulating. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / blood. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Autoantibodies / blood. Biopsy, Fine-Needle. Female. Humans. Iodine Radioisotopes. Male. Middle Aged. Neoplasm, Residual / blood. Neoplasm, Residual / diagnosis. Predictive Value of Tests. Preoperative Care. RNA, Messenger / blood. Sensitivity and Specificity. Thyroglobulin / immunology. Thyroid Nodule / blood. Thyroid Nodule / pathology. Thyroid Nodule / radionuclide imaging. Thyroid Nodule / surgery. Thyroidectomy. Whole Body Imaging

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118994.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Iodine Radioisotopes; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


85. Camera A, Magri F, Fonte R, Villani L, Della Porta MG, Fregoni V, Manna LL, Chiovato L: Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule. Thyroid; 2010 Sep;20(9):1033-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule.
  • BACKGROUND: Most solitary hyperfunctiong regions on thyroid scan consist of benign tissue.
  • SUMMARY: A 56-year-old man was referred to our Endocrine Unit in May 2009 due to the incidental discovery of a large left thyroid lobe nodule by a computed tomography study.
  • This had been performed to search for a primitive tumor in a patient with bone metastasis.
  • He was clinically and biochemically thyrotoxic with no evidence of humoral thyroid autoimmunity.
  • The nodule had a dyshomogenous appearance at neck ultrasonography, with multiple hypoechogenic areas and calcifications. (99m)-Technetium thyroid scintiscan revealed a hot nodule with suppression of the contralateral lobe.
  • Fine-needle aspiration cytology indicated the presence of neoplastic cells not of thyroid origin.
  • Histological analysis of the surgical specimen led to a diagnosis of Burkitt-like large B-cell lymphoma harbored within a thyroid adenoma.
  • After further staging, the final diagnosis was stage IV E Burkitt-like lymphoma with the involvement of the bone and the thyroid.
  • This is the first description of an aggressive Burkitt-like lymphoma that infiltrated an hyperfunctioning thyroid adenoma, thus presenting as a hot nodule at thyroid scintiscan.
  • In our patient there was no humoral or histological evidence of thyroid autoimmunity, thus suggesting a metastatic seeding of the lymphoma within the hyperfunctioning thyroid nodule.
  • CONCLUSIONS: Involvement of the thyroid gland by Burkitt-like lymphoma is extremely rare as is close localization of malignancy and a hyperfunctioning thyroid nodule.
  • [MeSH-major] Adenoma / diagnosis. Burkitt Lymphoma / diagnosis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Bone Neoplasms / secondary. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Humans. Hyperthyroidism / drug therapy. Hyperthyroidism / surgery. Male. Methimazole / therapeutic use. Middle Aged. Neoplasm Staging. Technetium. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHIMAZOLE .
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20825299.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 554Z48XN5E / Methimazole; 5J49Q6B70F / Vincristine; 7440-26-8 / Technetium; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


86. Rydlova M, Ludvikova M, Stankova I: Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Jun;152(1):53-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study.
  • AIMS: The differential diagnosis of thyroid nodules in routine practice can be problemmatic for both pathologists and clinicians.
  • The objective of this study was to evaluate the diagnostic usefulness of novel markers in the diagnosis of hyperplastic and neoplastic nodules.
  • METHODS: Forty eight thyroid lesions forming four diagnostic groups including adenomatous goiters (AS), follicular adenomas (FA), follicular (FC) and papillary carcinomas (PC) were examined using standard immunohistochemical methods.
  • Moreover, statistically significant differences between fused groups of benign (AS and FA) and malignant lesions (FC and PC) were found Fischer's exact test (p = 0.0001).
  • No significant differences in cytoplasmic expression of MMPs -2 and -7 and in vascular density assessed by using of both endothelial markers between benign lesions and malignant tumors were revealed.
  • CONCLUSIONS: Galectin-3 appears to be a useful marker in the diagnosis of papillary carcinoma only.
  • The matrix metalloproteinases-2 and -7 are not helpful in distinguishing hyperplastic and neoplastic thyroid nodules.
  • Endothelial markers do not appear to be suitable for thyroid differential diagnosis.
  • A panel of antibodies in the differential diagnosis of thyroid nodular lesions would seem most suitable and further studies with larger sets of patients are awaited.
  • [MeSH-major] Galectin 3 / analysis. Thyroid Neoplasms / diagnosis. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Male. Matrix Metalloproteinase 2 / analysis. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 7 / analysis. Microvessels / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795075.001).
  • [ISSN] 1213-8118
  • [Journal-full-title] Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
  • [ISO-abbreviation] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


87. Gong Y, Jalali M, Staerkel G: Fine needle aspiration cytology of a thyroid metastasis of metaplastic breast carcinoma: a case report. Acta Cytol; 2005 May-Jun;49(3):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a thyroid metastasis of metaplastic breast carcinoma: a case report.
  • Because of the heterogeneous nature of this tumor, cytologic interpretation on fine needle aspirates can be quite challenging.
  • This is especially true of metastatic lesions of this rare tumor type.
  • Metastasis to the thyroid has not been previously reported.
  • CASE: A 57-year-old woman with a history of metaplastic breast carcinoma for which she underwent mastectomy, chemotherapy and radiation therapy 2 years earlier presented with a fast-growing left thyroid mass with progressive hoarseness and dysphasia.
  • Clinical presentation and findings from a neck computed tomographic scan were strongly suggestive of a primary thyroid malignancy.
  • The aspirate specimen was composed of scant, highly atypical epithelial cells in a background of an abundant chondromyxoid matrix and scattered, benign follicular cells.
  • CONCLUSION: This case emphasizes the value of clinical information and the importance of generous sampling in achieving a correct diagnosis of metastatic metaplastic carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / secondary. Thyroid Gland / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966298.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Chesnokova V, Zonis S, Kovacs K, Ben-Shlomo A, Wawrowsky K, Bannykh S, Melmed S: p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A; 2008 Nov 11;105(45):17498-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21(Cip1) restrains pituitary tumor growth.
  • As commonly encountered, pituitary adenomas are invariably benign.
  • Pituitary tumor transforming gene (Pttg) deletion results in pituitary p21 induction and abrogates tumor development in Rb(+/-)Pttg(-/-) mice. p21 disruption restores attenuated Rb(+/-)Pttg(-/-) pituitary proliferation rates and enables high penetrance of pituitary, but not thyroid, tumor growth in triple mutant animals (88% of Rb(+/-) and 72% of Rb(+/-)Pttg(-/-)p21(-/-) vs. 30% of Rb(+/-)Pttg(-/-) mice developed pituitary tumors, P < 0.001).
  • Intranuclear p21 accumulates in Pttg-null aneuploid GH-secreting cells, and GH(3) rat pituitary tumor cells overexpressing PTTG also exhibited increased levels of mRNA for both p21 (18-fold, P < 0.01) and ATM (9-fold, P < 0.01).
  • Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] Oncogene. 2000 Nov 9;19(47):5338-47 [11103935.001]
  • [Cites] Mod Pathol. 2001 Jan;14(1):20-8 [11211306.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 15;29(6):1300-7 [11238996.001]
  • [Cites] Oncogene. 2001 Feb 22;20(8):962-71 [11314031.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6234-8 [11507077.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):168-70 [14755273.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):792-804 [15459660.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5293-303 [10498881.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):5013-25 [16030261.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):11-23 [16372018.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):459-71 [16766265.001]
  • [Cites] Neurosurgery. 2006 Aug;59(2):341-53; discussion 341-53 [16883174.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):220-30 [16932287.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):24731-42 [17569660.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cell. 2007 Oct 19;131(2):309-23 [17956732.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] J Cell Sci. 2000 Oct;113 ( Pt 20):3613-22 [11017877.001]
  • (PMID = 18981426.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / CA75979
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; 0 / Securin; 0 / Tumor Suppressor Proteins; 0 / pituitary tumor-transforming protein 1, human; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


89. Martino F, Avila LF, Encinas JL, Luis AL, Olivares P, Lassaletta L, Nistal M, Tovar JA: Teratomas of the neck and mediastinum in children. Pediatr Surg Int; 2006 Aug;22(8):627-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recorded prenatal diagnosis, perinatal management, clinical and radiologic features, pathology, surgical strategies and results in cervical and mediastinal teratomas treated over the last 10 years.
  • Prenatal diagnosis was made in three (two with polyhydramnios).
  • The diagnosis was confirmed by imaging and increased AFP.
  • Surgical treatment involved total tumor removal and in one case subsequent removal of lymph node metastases.
  • Prenatal diagnosis and planned multidisciplinary management are mandatory at birth.
  • Although benign, these tumors are sometimes immature and may metastasize to regional lymph nodes.
  • Thyroid insufficiency may be present at birth in cervical teratomas and may be aggravated by surgery.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / surgery. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Fetal Diseases / surgery. Humans. Infant. Infant, Newborn. Male. Pregnancy. Prenatal Diagnosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Perinat Med. 2004;32(6):500-8 [15576271.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):446-50; discussion 446-50 [12632365.001]
  • [Cites] Eur J Pediatr Surg. 2000 Aug;10(4):252-7 [11034516.001]
  • [Cites] J Pediatr Surg. 2004 Jul;39(7):1003-13 [15213888.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Nov;86(5):727-31 [6632945.001]
  • [Cites] Am J Perinatol. 1998 Apr;15(4):253-7 [9565224.001]
  • [Cites] J Pediatr Surg. 2003 Apr;38(4):E12 [12677599.001]
  • [Cites] J Pediatr Surg. 1986 Jun;21(6):548-51 [2425069.001]
  • [Cites] J Pediatr Surg. 1995 Feb;30(2):312-6 [7537809.001]
  • [Cites] Pediatr Surg Int. 1998 Dec;14(3):212-3 [9880752.001]
  • [Cites] Acta Obstet Gynecol Scand. 1982;61(1):7-12 [7046336.001]
  • [Cites] Histopathology. 1988 May;12(5):491-502 [3397045.001]
  • [Cites] Am Surg. 1997 May;63(5):459-61 [9128238.001]
  • [Cites] Eur Radiol. 2003 Jul;13(7):1538-48 [12695920.001]
  • [Cites] J Pediatr Surg. 1983 Aug;18(4):382-6 [6620078.001]
  • [Cites] Semin Diagn Pathol. 1999 Feb;16(1):42-50 [10355653.001]
  • [Cites] Z Kinderchir. 1982 Jan;35(1):9-11 [7064584.001]
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):21-3 [2723988.001]
  • [Cites] Fetal Diagn Ther. 2005 May-Jun;20(3):214-8 [15824501.001]
  • [Cites] J Pediatr Surg. 1998 Apr;33(4):553-8 [9574750.001]
  • [Cites] J Otolaryngol. 1997 Aug;26(4):246-52 [9263894.001]
  • [Cites] AJR Am J Roentgenol. 1997 Oct;169(4):985-90 [9308448.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):18-24 [11150432.001]
  • [Cites] J Pediatr Surg. 1988 Jun;23(6):583-91 [3047360.001]
  • [Cites] J Pediatr Surg. 1993 Sep;28(9):1161-4 [7508501.001]
  • [Cites] Pediatr Surg Int. 2000;16(5-6):333-7 [10955557.001]
  • [Cites] Ultrasound Obstet Gynecol. 2001 Nov;18(5):543-6 [11844182.001]
  • [Cites] J Pediatr Surg. 2003 Dec;38(12):1846 [14666486.001]
  • [Cites] J Pediatr Surg. 1999 Nov;34(11):1633-7 [10591558.001]
  • [Cites] J Clin Ultrasound. 1984 Oct;12(8):509-11 [6436332.001]
  • [Cites] Pediatr Radiol. 1998 Sep;28(9):709-10 [9732501.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Aug;25(7):1251-5 [15313719.001]
  • [Cites] Prenat Diagn. 1993 Dec;13(12 ):1079-84 [8177827.001]
  • [Cites] Plast Reconstr Surg. 1986 Mar;77(3):469-73 [3513222.001]
  • [Cites] AJR Am J Roentgenol. 1982 Dec;139(6):1220-2 [6983274.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2004 Sep;68(9):1133-9 [15302143.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S229-41 [10517457.001]
  • [Cites] Prenat Diagn. 1994 Sep;14 (9):884-7 [7845899.001]
  • [Cites] Am J Obstet Gynecol. 1997 Oct;177(4):870-4 [9369836.001]
  • [Cites] J Pediatr Surg. 2001 Aug;36(8):1244-7 [11479867.001]
  • [Cites] Surgery. 1976 Sep;80(3):297-305 [960000.001]
  • [Cites] Mayo Clin Proc. 1986 Jul;61(7):546-55 [3086634.001]
  • [Cites] Eur Radiol. 1998;8(1):100-2 [9442139.001]
  • [Cites] Pediatr Radiol. 2001 Oct;31(10):727-31 [11685443.001]
  • [Cites] Prog Pediatr Surg. 1981;14:225-39 [7221009.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] J Pediatr. 1974 Jul;85(1):139-40 [4852867.001]
  • [Cites] Anesthesiology. 1998 Dec;89(6):1573-5 [9856736.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Nov;262(11):899-904 [15895292.001]
  • [Cites] Pediatr Surg Int. 2001 Mar;17(2-3):235-8 [11315301.001]
  • [Cites] Surg Today. 1994;24(10):923-5 [7894193.001]
  • [Cites] Am J Perinatol. 2001 Nov;18(7):357-62 [11731888.001]
  • [Cites] Am J Perinatol. 1992 Sep-Nov;9(5-6):445-7 [1418153.001]
  • [Cites] J Matern Fetal Med. 1999 Nov-Dec;8(6):295-7 [10582864.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):367-76 [12518361.001]
  • [Cites] J Ultrasound Med. 1995 Sep;14 (9):673-8 [7500433.001]
  • [Cites] J Thorac Imaging. 1987 Apr;2(2):66-71 [3599151.001]
  • [Cites] J Pediatr Surg. 2002 Mar;37(3):418-26 [11877660.001]
  • (PMID = 16838188.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Beil CM, Keberle M: Oral and oropharyngeal tumors. Eur J Radiol; 2008 Jun;66(3):448-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is a large variability of tumors and tumor-like lesions, which are located in the oral cavity and oropharynx.
  • About 10% of all oral and oropharyngeal tumors are benign.
  • Congenital lesions, like vascular malformations, lingual thyroid or (epi-)dermoid cyst, usually become present in youth or childhood.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Diagnostic Imaging. Mouth Neoplasms / diagnosis. Oropharyngeal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18457933.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 18
  •  go-up   go-down


91. Salomäki HH, Sainio AO, Söderström M, Pakkanen S, Laine J, Järveläinen HT: Differential expression of decorin by human malignant and benign vascular tumors. J Histochem Cytochem; 2008 Jul;56(7):639-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of decorin by human malignant and benign vascular tumors.
  • Given that angiogenesis is a sine qua non for tumor growth and progression, we attempted to examine whether human malignant vascular tumors differ from human benign vascular tumors in terms of their decorin expression and synthesis.
  • CD31 immunostaining demonstrated that the human malignant vascular tumors Kaposi's sarcoma and angiosarcoma were filled with capillary-like structures, whereas in benign cavernous and capillary hemangiomas, blood vessels were not as abundantly present.
  • By utilizing in situ hybridization and immunocytochemical assays for decorin, we showed that there was no detectable decorin mRNA expression or immunoreactivity within the tumor mass in the Kaposi's sarcoma or angiosarcoma group.
  • In contrast to sarcomas, in hemangiomas, decorin mRNA expression and immunoreactivity were observed also within the tumor mass, particularly in the connective tissue stroma surrounding the clusters of intratumoral blood vessels.
  • Finally, distribution of type I collagen was found to be similar to that of decorin in these tumor tissues.
  • Thus, decorin is likely to possess a suppressive effect on human tumor angiogenesis in vivo, as previously described by studies using different experimental models.
  • Decorin certainly provides a usable biomarker for distinguishing between benign and malignant vascular tumors in patients.
  • [MeSH-major] Extracellular Matrix Proteins / biosynthesis. Hemangioma, Capillary / metabolism. Hemangioma, Cavernous / metabolism. Hemangiosarcoma / metabolism. Proteoglycans / biosynthesis. Sarcoma, Kaposi / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Collagen Type I / metabolism. Decorin. Female. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged. RNA, Messenger / biosynthesis. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 May 5;275(18):13924-32 [10788518.001]
  • [Cites] J Cell Physiol. 2008 Mar;214(3):559-67 [17894407.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):345-53 [11159170.001]
  • [Cites] Microvasc Res. 2001 Jul;62(1):26-42 [11421658.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40687-92 [11546775.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3688-95 [12032837.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4765-77 [12101415.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):207-14 [12538471.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):869-78 [12937128.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):482-8 [14976536.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 24;322(3):943-9 [15336555.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):509-17 [15349825.001]
  • [Cites] Matrix. 1989;9(6):468-78 [2635760.001]
  • [Cites] J Biol Chem. 1990 Jul 5;265(19):11389-96 [2162845.001]
  • [Cites] Exp Cell Res. 1992 Dec;203(2):395-401 [1281110.001]
  • [Cites] Eur J Cell Biol. 1992 Dec;59(2):314-21 [1493796.001]
  • [Cites] Biochem J. 1994 Sep 1;302 ( Pt 2):527-34 [8093006.001]
  • [Cites] J Invest Dermatol. 1995 Apr;104(4):509-13 [7706768.001]
  • [Cites] Acta Orthop Scand Suppl. 1995 Oct;266:61-5 [8553864.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18961-5 [8702560.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1997;32(2):141-74 [9145286.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):149-57 [9202067.001]
  • [Cites] J Clin Invest. 1998 Jan 15;101(2):406-12 [9435313.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28116-21 [9774430.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4489-92 [9988678.001]
  • [Cites] Eur J Cell Biol. 1999 Jan;78(1):44-55 [10082423.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12):7402-8 [10358193.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1104-10 [15690056.001]
  • [Cites] Thyroid. 2005 Mar;15(3):210-21 [15785240.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):15767-72 [15701628.001]
  • [Cites] Semin Diagn Pathol. 2004 Aug;21(3):166-218 [15912727.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):27935-48 [15923192.001]
  • [Cites] Wound Repair Regen. 2006 Jul-Aug;14(4):443-52 [16939572.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1324-32 [16949929.001]
  • [Cites] Cancer Cell. 2007 Jun;11(6):539-54 [17560335.001]
  • [Cites] J Surg Oncol. 2007 Oct 1;96(5):411-8 [17579351.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • (PMID = 18413650.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / DCN protein, human; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2430166
  •  go-up   go-down


92. Turker O, Dogan I, Kumanlioglu K: Radioiodine accumulation in a large adnexal cystadenofibroma. Thyroid; 2010 May;20(5):561-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Posttherapy or diagnostic whole-body radioiodine (131I) scans are conducted to observe metastases of differentiated thyroid carcinomas.
  • Here we report a patient with marked radioiodine accumulation in a large adnexal cystadenofibroma, a benign ovarian tumor.
  • Pathologic examination revealed multifocal papillary thyroid carcinoma.
  • The residual thyroid tissue was ablated with 3.7 GBq radioiodine (131I) when the serum thyroglobulin concentration was 28.7 ng/mL and the serum thyroid-stimulating hormone level was 50 microIU/mL.
  • Pathologic examination revealed a benign cystadenofibroma without any coexisting thyroid tissue.
  • The mechanism for radioiodine accumulation in this patient's tumor is unclear.
  • [MeSH-major] Cystadenoma / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Papillary / radiotherapy. Carcinoma, Papillary / surgery. False Positive Reactions. Female. Goiter, Nodular / surgery. Humans. Hysterectomy. Iodine Radioisotopes / pharmacokinetics. Middle Aged. Ovariectomy. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406107.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


93. Mijovic T, Gologan O, Rochon L, Hier M, Black MJ, Young J, Rivera J, Tamilia M, Payne RJ: Fine-needle aspiration biopsy of the thyroid: review of cytopathologic features predictive of malignancy. J Otolaryngol Head Neck Surg; 2009 Jun;38(3):348-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of the thyroid: review of cytopathologic features predictive of malignancy.
  • OBJECTIVE: To determine the value of specific cytopathologic features on fine-needle aspiration biopsies (FNABs) at predicting thyroid malignancy.
  • DESIGN: Retrospective review of consecutive patients undergoing thyroidectomy between 2005 and 2007 following FNAB of thyroid nodules.
  • METHODS: One hundred forty-seven patients were reviewed and further categorized into two groups (benign vs malignant) based on the final histopathologic diagnosis.
  • Alternatively, siderophages (44% vs 23%; p = .007) and honeycomb arrangements (92% vs 60%; p = .012) were more associated with benign processes.
  • CONCLUSION: Some cytopathologic features are more significantly associated with thyroid malignancy.
  • The cytopathologic features listed in FNAB reports and HBME-1 immunoreactivity are, alone or in combination, additional tools available to the physician to guide management of thyroid nodules.
  • [MeSH-major] Biopsy, Fine-Needle. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476767.001).
  • [ISSN] 1916-0216
  • [Journal-full-title] Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  • [ISO-abbreviation] J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen
  •  go-up   go-down


94. Xu J, Capezzone M, Xu X, Hershman JM: Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells. Mol Endocrinol; 2005 Feb;19(2):527-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.
  • We previously demonstrated that the human nicotinamide N-methytransferase (NNMT) gene was highly expressed in many papillary thyroid cancers and cell lines.
  • The expression in other papillary and follicular cancers or cell lines and normal thyroid cells was low or undetectable.
  • BHP 14-9) NNMT gene expression, and expressed weakly in follicular thyroid cancer cell lines.
  • HNF-1beta was not expressed or expressed very weakly in other papillary, follicular, and Hurthle cancer cell lines and primary cultures of normal thyroid cells and benign thyroid conditions.
  • Cotransfection of a HNF-1beta expression plasmid increased NNMT promoter activity significantly in both HNF-1beta-positive and -negative thyroid cancer cell lines and Hep G2 liver cancer cells.
  • In summary, HNF-1beta functions as a transcription activator for NNMT gene expression in some papillary thyroid cancer cells.
  • [MeSH-major] Adenocarcinoma, Papillary / enzymology. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Methyltransferases / genetics. Methyltransferases / metabolism. Promoter Regions, Genetic. Thyroid Neoplasms / enzymology. Transcription Factors / metabolism
  • [MeSH-minor] Base Sequence. Binding Sites. Blotting, Western. Catalysis. Cell Line. Cell Line, Tumor. Cell Nucleus / metabolism. Cloning, Molecular. Enzyme Activation. Gene Deletion. Genes, Reporter. Hepatocyte Nuclear Factor 1-beta. Humans. Luciferases / metabolism. Molecular Sequence Data. Mutation. Nicotinamide N-Methyltransferase. Plasmids / metabolism. Protein Binding. Reverse Transcriptase Polymerase Chain Reaction. Thyroid Gland / metabolism. Transcriptional Activation. Transfection

  • Genetic Alliance. consumer health - Thyroid cancer, papillary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15486044.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / HNF1B protein, human; 0 / Transcription Factors; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta; EC 1.13.12.- / Luciferases; EC 2.1.1.- / Methyltransferases; EC 2.1.1.1 / NNMT protein, human; EC 2.1.1.1 / Nicotinamide N-Methyltransferase
  •  go-up   go-down


95. Kurli M, Reddy S, Tena LB, Pavlick AC, Finger PT: Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol; 2005 Aug;140(2):193-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two were imaged before treatment of their primary tumor.
  • The mean time from initial diagnosis to metastasis was 47 months (range 0 to 154).
  • Cardiac, brain, thyroid, and posterior abdominal wall lesions (12.5%) were also noted.
  • PET/computed tomography imaging also detected benign lesions of the bone and lymph nodes in three patients (15%).
  • [MeSH-major] Choroid Neoplasms / pathology. Choroid Neoplasms / radionuclide imaging. Melanoma / radionuclide imaging. Melanoma / secondary. Positron-Emission Tomography / methods. Whole-Body Counting / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15992753.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


96. Palermo S, Di Matteo FM, Savino G, Di Marco C, Catania A, De Antoni E: [Micromedullary thyroid carcinoma: school experience]. G Chir; 2010 Jun-Jul;31(6-7):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Micromedullary thyroid carcinoma: school experience].
  • [Transliterated title] Il microcarcinoma midollare della tiroide: esperienza di Scuola.
  • Medullary microcarcinomas occurrence are rare and fortuitous, it's usually related to the calcitonin measurement, that's the gold standard for the diagnosis.
  • In other cases performing a thyroidectomy for a benign thyroid disease it's found a sub-centimeter tumor.
  • In this study 17 patients were operated for medullary thyroid microcarcinoma and the Authors found central lymph node metastases in 33.3% of cases.
  • [MeSH-major] Carcinoma, Medullary / diagnosis. Carcinoma, Medullary / surgery. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / surgery. Thyroidectomy / methods

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646376.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 9007-12-9 / Calcitonin
  •  go-up   go-down


97. Lyshchik A, Higashi T, Asato R, Tanaka S, Ito J, Mai JJ, Pellot-Barakat C, Insana MF, Brill AB, Saga T, Hiraoka M, Togashi K: Thyroid gland tumor diagnosis at US elastography. Radiology; 2005 Oct;237(1):202-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid gland tumor diagnosis at US elastography.
  • PURPOSE: To prospectively evaluate the elastographic appearance of thyroid gland tumors and explore the potential sensitivity and specificity of ultrasonographic (US) elastography for differentiating benign and malignant tumors, with histopathologic analysis as the reference standard.
  • Fifty-two thyroid gland lesions (22 malignant, 30 benign) in 31 consecutive patients (six men, 25 women; mean age, 49.7 years +/- 14.7 [standard deviation]) were examined with real-time elastography in the elasticity imaging mode implemented on a clinical US scanner modified for research.
  • In addition, normal thyroid gland tissue and thyroid gland tumor strains were measured on off-line processed elastograms, and the thyroid gland-to-tumor strain ratio (ie, strain index) was calculated.
  • The potential of elastographic criteria for the diagnosis of thyroid gland cancer was evaluated with univariate analysis and multivariate logistic regression.
  • RESULTS: A strain index value greater than 4 on off-line processed elastograms was the strongest independent predictor of thyroid gland malignancy (P < .001); this criterion had 96% specificity and 82% sensitivity.
  • Two other elastographic criteria, which were evaluated on real-time elastograms--a margin regularity score higher than 3 (88% specificity, 36% sensitivity) and a tumor area ratio higher than 1 (92% specificity, 46% sensitivity)--also were associated with malignancy (P < .05).
  • CONCLUSION: Elastography is a promising imaging technique that can assist in the differential diagnosis of thyroid cancer.
  • [MeSH-major] Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Biomechanical Phenomena. Cysts / ultrasonography. Diagnosis, Differential. Elasticity. Female. Humans. Logistic Models. Male. Middle Aged. Sensitivity and Specificity. Thyroid Diseases / ultrasonography

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005
  • (PMID = 16118150.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


98. Kim E, Bae TS, Kwon Y, Kim TH, Chung KW, Kim SW, Ro J, Lee ES: Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report. J Korean Med Sci; 2007 Jun;22(3):568-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.
  • Most teratomas involving the thyroid are benign and occur in children.
  • However, the adult cases reported are mostly malignant and commonly arise in the thyroid.
  • The patient underwent extensive evaluation of the thyroid gland with computed tomography (CT) scan and positron emission tomography (PET) scan, which revealed no evidence of metastatic disease.
  • This is the first case, to our knowledge, of malignant thyroid teratoma with a exuberant primitive neuroectodermal tumor component in Korea.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / complications. Neuroectodermal Tumors, Primitive / pathology. Teratoma / complications. Teratoma / pathology. Thyroid Gland / pathology
  • [MeSH-minor] Adult. Female. Head and Neck Neoplasms / pathology. Humans. Neoplasm Metastasis. Positron-Emission Tomography / methods. Thyroid Diseases / diagnosis. Thyroidectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 1;88(5):1149-58 [10699906.001]
  • [Cites] Am J Otolaryngol. 2000 Mar-Apr;21(2):112-5 [10758996.001]
  • [Cites] Acta Cytol. 2000 May-Jun;44(3):375-9 [10833994.001]
  • [Cites] Ann Diagn Pathol. 2001 Oct;5(5):285-92 [11598856.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] Thyroid. 2003 Apr;13(4):401-4 [12804109.001]
  • [Cites] Ann Oncol. 1998 Sep;9(9):1015-22 [9818077.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2796-804 [7595741.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):896-904 [9255252.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):212-4 [9537215.001]
  • [Cites] Ann Hematol. 1998 May;76(5):183-8 [9671130.001]
  • [Cites] Head Neck. 1998 Oct;20(7):649-53 [9744468.001]
  • [Cites] Bull Cancer. 1995;82 Suppl 1:56s-60s [7542945.001]
  • (PMID = 17596674.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2693658
  •  go-up   go-down


99. Avcu S, Ozen O, Bulut MD, Bora A: Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci; 2009 Nov;1(6):305-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.
  • CONTEXT: Carcinoid tumors represent a group of well-differentiated tumors originating from the diffuse endocrine system outside the pancreas and thyroid.
  • Various sites of origin of this neoplasm are appendix - 30-45%, small bowel - 25-35% (duodenum 2%, jejunum 7%, ileum 91%, multiple sites 15-35%), rectum 10-15%, caecum - 5%, and stomach - 0.5%.
  • CASE REPORT: Here we report a case of primary jejunal carcinoid tumor in a 66-year-old woman metastasizing to liver with ultrasonography, computed tomography, and diffusion-weighted magnetic resonance imaging (DWI) findings.
  • CONCLUSION: Primary jejunal carcinoid tumor is a rare entity.
  • DWI can help in the differential diagnosis of hepatic hypervascular metastatic mass lesions from benign ones, as well as in the diagnosis of carcinoid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666712.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364631
  • [Keywords] NOTNLM ; Carcinoid / diffusion weighted MRI / jejunum / metastases / small bowel
  •  go-up   go-down


100. Torregrossa L, Faviana P, Filice ME, Materazzi G, Miccoli P, Vitti P, Fontanini G, Melillo RM, Santoro M, Basolo F: CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1. Thyroid; 2010 May;20(5):495-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1.
  • BACKGROUND: The cytological discrimination between benign and malignant follicular-patterned lesions of the thyroid can represent a diagnostic challenge, even for experienced pathologists.
  • We evaluated the diagnostic use of protein expression of CXC chemokine receptor 4 (CXCR4) and galectin-3 (gal-3) that were found to be upregulated in papillary thyroid carcinoma compared to normal thyroid and of mesothelial cell surface protein recognized by monoclonal antibody Hector Battifora Mesothelial cell (HBME)-1 in thyroid tumors.
  • METHODS: Expression of CXCR4, HBME-1, and gal-3 was examined immunohistochemically in total of 100 aspirates of thyroid lesions, categorized as benign (n = 22), indeterminate lesion (n = 43), suspicious of papillary thyroid carcinoma (n = 10), or malignant (n = 25) by preoperative cytology.
  • CONCLUSIONS: An immunohistochemical panel, including CXCR4, could be useful in the differential diagnosis between benign and malignant well-differentiated follicular-patterned thyroid lesions.
  • [MeSH-major] Biomarkers, Tumor / chemistry. Carcinoma, Papillary, Follicular / chemistry. Galectin 3 / chemistry. Receptors, CXCR4 / chemistry. Thyroid Neoplasms / genetics
  • [MeSH-minor] Biopsy, Fine-Needle. Humans. Immunohistochemistry. Thyroid Nodule / pathology. Thyroid Nodule / surgery

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450430.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Receptors, CXCR4
  •  go-up   go-down






Advertisement